<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement - Franco, JVA - 2023 | Cochrane Library</title> <meta content="Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement - Franco, JVA - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001423.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement - Franco, JVA - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001423.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001423.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement" name="citation_title"/> <meta content="Juan VA Franco" name="citation_author"/> <meta content="Heinrich-Heine-University Düsseldorf" name="citation_author_institution"/> <meta content="juan.franco@med.uni-duesseldorf.de" name="citation_author_email"/> <meta content="Leonel Trivisonno" name="citation_author"/> <meta content="Universidad Nacional de La Matanza" name="citation_author_institution"/> <meta content="Nadia J Sgarbossa" name="citation_author"/> <meta content="Universidad Nacional de La Matanza" name="citation_author_institution"/> <meta content="Gustavo Ariel Alvez" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Cecilia Fieiras" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Camila Micaela Escobar Liquitay" name="citation_author"/> <meta content="Instituto Universitario Hospital Italiano de Buenos Aires" name="citation_author_institution"/> <meta content="Jae Hung Jung" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD001423.pub4" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001423.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001423.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001423.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Plant Extracts [adverse effects]; *Prostatic Hyperplasia [complications, drug therapy]; Quality of Life; Serenoa" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001423.pub4&amp;doi=10.1002/14651858.CD001423.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001423\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001423\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001423.pub4",title:"Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement",firstPublishedDate:"Jun 22, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001423.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001423.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001423.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001423.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001423.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001423.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001423.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001423.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001423.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001423.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5206 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001423.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-sec-0088"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/appendices#CD001423-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/supinfo/CD001423-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/supinfo/CD001423-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#CD001423-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Juan VA Franco</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#CD001423-cr-0005">Leonel Trivisonno</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#CD001423-cr-0006">Nadia J Sgarbossa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#CD001423-cr-0007">Gustavo Ariel Alvez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#CD001423-cr-0008">Cecilia Fieiras</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#CD001423-cr-0009">Camila Micaela Escobar Liquitay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information#CD001423-cr-0010">Jae Hung Jung</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information/en#CD001423-sec-0133">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001423.pub4">https://doi.org/10.1002/14651858.CD001423.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001423-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001423-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001423-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001423-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001423-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001423-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD001423-abs-0008">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001423-abs-0001" lang="en"> <section id="CD001423-sec-0001"> <h3 class="title" id="CD001423-sec-0001">Background</h3> <p>Benign prostatic hyperplasia (BPH) is a non‐malignant enlargement of the prostate, which can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH is common. The extract of the berry of the American saw palmetto or dwarf palm plant, <i>Serenoa repens</i> (SR), which is also known by its botanical name of <i>Sabal serrulatum</i>, is one of several phytotherapeutic agents available for the treatment of BPH. </p> </section> <section id="CD001423-sec-0002"> <h3 class="title" id="CD001423-sec-0002">Objectives</h3> <p>To assess the effects of <i>Serenoa repens</i> in the treatment of men with LUTS consistent with BPH. </p> </section> <section id="CD001423-sec-0003"> <h3 class="title" id="CD001423-sec-0003">Search methods</h3> <p>We performed a comprehensive search of multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to 16 September 2022, with no restrictions on language or publication status. </p> </section> <section id="CD001423-sec-0004"> <h3 class="title" id="CD001423-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials of participants with BPH who were treated with <i>Serenoa repens</i> or placebo/no treatment. </p> </section> <section id="CD001423-sec-0005"> <h3 class="title" id="CD001423-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion at each stage and undertook data extraction and risk of bias assessment and GRADE assessment of the certainty of the evidence. We considered review outcomes measured up to 12 months after randomization as short term, and beyond 12 months as long term. Our main outcomes included urologic symptom scores, quality of life, and adverse events. </p> </section> <section id="CD001423-sec-0006"> <h3 class="title" id="CD001423-sec-0006">Main results</h3> <p>For this update, we narrowed the review question to only comparisons with placebo. We included 27 studies (of which 9 were new) involving a total of 4656 participants, 19 studies comparing <i>Serenoa repens</i> with placebo, and 8 studies comparing <i>Serenoa repens</i> in combination with other phytotherapeutic agents versus placebo. Most studies included men aged &gt; 50 (mean age range 52 to 68) with moderate urologic symptoms (International Prostate Symptom Score [IPSS] range 8 to 19). Ten studies were funded by the pharmaceutical industry; two studies were funded by government agencies; and the remaining studies did not specify funding sources. </p> <p><b><i>Serenoa repens</i> versus placebo or no intervention</b> </p> <p>Results for this comparison are based on predefined sensitivity analyses limited to studies at low risk of bias. <i>Serenoa repens</i> results in little to no difference in urologic symptoms at short‐term follow‐up (3 to 6 months; IPSS score range 0 to 35, higher scores indicate worse symptoms; mean difference (MD) −0.90, 95% confidence interval (CI) −1.74 to −0.07; I<sup>2</sup> = 68%; 9 studies, 1681 participants; high‐certainty evidence). <i>Serenoa repens</i> results in little to no difference in the quality of life at short‐term follow‐up (3 to 6 months; IPSS quality of life domain range 0 to 6, higher scores indicate worse quality of life; MD −0.20, 95% CI −0.40 to −0.00; I<sup>2</sup> = 39%; 5 studies, 1001 participants; high‐certainty evidence). <i>Serenoa repens</i> probably results in little to no difference in adverse events (1 to 17 months; risk ratio (RR) 1.01, 95% CI 0.77 to 1.31; I<sup>2</sup> = 18%; 12 studies, 2399 participants; moderate‐certainty evidence). Based on 164 cases per 1000 men in the placebo group, this corresponds to 2 more (38 fewer to 51 more) per 1000 men in the <i>Serenoa repens</i> group. </p> <p><i>Serenoa repens</i> results in little to no difference in urologic symptoms at long‐term follow‐up (12 to 17 months, IPSS score, MD 0.07, 95% CI −0.75 to 0.88; I<sup>2</sup> = 34%; 3 studies, 898 participants; high‐certainty evidence). <i>Serenoa repens</i> results in little to no difference in quality of life at long‐term follow‐up (12 to 17 months, IPSS quality of life, MD −0.11, 95% CI −0.41 to 0.19; I<sup>2</sup> = 65%; 3 studies, 882 participants; high‐certainty evidence). There were no data on long‐term adverse events for this comparison. </p> <p><b><i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention</b> </p> <p>Different phytotherapeutic agents that include <i>Serenoa repens</i> may result in little to no difference in urologic symptoms compared to placebo at short‐term follow‐up (12 to 24 weeks, IPSS score, MD −2.41, 95% CI −4.54 to −0.29; I<sup>2</sup> = 67%; 4 studies, 460 participants; low‐certainty evidence). We are very uncertain about the effects of these agents on quality of life (very low‐certainty evidence). These agents may result in little to no difference in the occurrence of adverse events; however, the CIs included substantial benefits and harms (12 to 48 weeks, RR 0.91, 95% CI 0.58 to 1.41; I<sup>2</sup> = 0%; 4 studies, 481 participants; low‐certainty evidence). Based on 132 cases per 1000 men in the placebo group, this corresponds to 12 fewer (55 fewer to 54 more) per 1000 men in the combined phytotherapeutic agents with <i>Serenoa repens</i> group. </p> </section> <section id="CD001423-sec-0007"> <h3 class="title" id="CD001423-sec-0007">Authors' conclusions</h3> <p><i>Serenoa repens</i> alone provides little to no benefits for men with lower urinary tract symptoms due to benign prostatic enlargement. There is more uncertainty about the role of <i>Serenoa repens</i> in combination with other phytotherapeutic agents. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001423-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001423-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001423-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001423-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001423-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001423-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001423-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001423-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001423-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001423-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001423-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001423-abs-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001423-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001423-abs-0002" lang="en"> <h3>Serenoa repens for benign prostatic hyperplasia</h3> <p><b>Review question</b> </p> <p>Does <i>Serenoa repens</i> alone or in combination with other phytotherapeutic agents improve symptoms in men with benign prostatic enlargement? </p> <p><b>Background</b> </p> <p>An enlarged prostate may cause bothersome urinary tract symptoms, such as having to urinate often during the day or night, having a weak stream, and the feeling of not completely emptying the bladder. Besides other common drug interventions, using plants and herbs (phytotherapy) is common and has been growing steadily in most Western countries. The extract of the berry of the American saw palmetto, or dwarf palm plant, <i>Serenoa repens</i> , which is also known by its botanical name of <i>Sabal serrulatum</i>, is one of several phytotherapeutic agents available for the treatment of this condition. </p> <p><b>Study characteristics</b> </p> <p>We found 27 studies with 4656 men comparing <i>Serenoa repens</i> alone or in combination with other herbal products to a placebo (participants are made to believe they received treatment when in fact they did not). Most studies included men over 50 with moderate symptoms. Ten studies were funded by pharmaceutical organizations; two studies received government funding; and the remaining studies did not specify funding sources. </p> <p><b>Key results</b> </p> <p>Based on the most trustworthy studies, <i>Serenoa repens</i> alone results in little to no difference in urinary tract symptoms or quality of life compared to placebo at three to six months. This treatment is also likely not associated with adverse events. Results were similar at 12 to 17 months. </p> <p><i>Serenoa repens</i> in combination with other herbal products may result in little to no difference in urinary tract symptoms, but there is more uncertainty about effects on quality of life and adverse events. </p> <p>The findings of this review are current to 16 September 2022.</p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of the evidence is primarily high or moderate for <i>Serenoa repens</i> alone, but low for <i>Serenoa repens</i> in combination with other agents, meaning our confidence in the results is high, moderate, or low. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001423-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001423-sec-0088"></div> <h3 class="title" id="CD001423-sec-0089">Implications for practice</h3> <section id="CD001423-sec-0089"> <p><i>Serenoa repens</i> alone provides little to no benefits for men with lower urinary tract symptoms due to benign prostatic enlargement. There is more uncertainty about the role of <i>Serenoa repens</i> in combination with other phytotherapeutic agents. </p> </section> <h3 class="title" id="CD001423-sec-0090">Implications for research</h3> <section id="CD001423-sec-0090"> <p>Considering the uncertainties about the effects of <i>Serenoa repens</i> in higher doses or combined with other herbal treatments, future high‐quality, placebo‐controlled randomized controlled trials are needed in this area that focus on patient‐important outcomes, including urologic symptoms, quality of life, and adverse events. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001423-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001423-sec-0008"></div> <div class="table" id="CD001423-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Serenoa repens compared to placebo or no intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>Serenoa repens</i> compared to placebo or no intervention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> lower urinary tract symptoms due to benign prostatic hyperplasia </p> <p><b>Setting</b>: outpatient (Australia, Asia, Europe, and the USA) </p> <p><b>Intervention</b>: <i>Serenoa repens</i> </p> <p><b>Comparison</b>: placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with <i>Serenoa repens</i> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom score</b><br/>Measured by IPSS scores (range 0 to 35)<br/>Higher scores indicate worse symptoms.<br/>Follow‐up: 3 to 6 months </p> <p>MCID: 3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1681</p> <p>(9 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −0.90</p> <p>(−1.74 to −0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean score was 14.33.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.90 lower</b> (1.74 lower to 0.07 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/>Measured by IPSS‐QoL score (range 0 to 6)<br/>Follow‐up: 3 to 6 months </p> <p>MCID: 0.5 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1001</p> <p>(5 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −0.20</p> <p>(−0.40 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean score was 3.11.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.20 lower</b> (0.40 lower to 0.00 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>Cumulative incidence<br/>Follow‐up: 1 to 17 months </p> <p>MCID: relative risk reduction/increase of 0.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2399</p> <p>(12 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> </p> <p>(0.77 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1000 (38 fewer to 51 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS</b> : International Prostate Symptom Score; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>QoL</b> : quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade the certainty of the evidence for risk of bias as these results were robust following sensitivity analysis excluding studies at high risk of bias. <br/><sup>b</sup>We did not downgrade the certainty of the evidence for risk of bias as these results were robust following sensitivity analysis excluding studies at high risk of bias. We downgraded one level due to imprecision as the CI included little to no benefit and also harms (based on a 25% relative risk reduction). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001423-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Serenoa repens in combination with other phytotherapy versus placebo or no intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> lower urinary tract symptoms due to benign prostatic hyperplasia </p> <p><b>Setting</b>: outpatient (Europe/USA) </p> <p><b>Intervention</b>: <i>Serenoa repens</i> with other phytotherapy </p> <p><b>Comparison</b>: placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with <i>Serenoa repens</i> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom score</b><br/>Measured by IPSS scores (range 0 to 35)<br/>Higher scores indicate worse symptoms.<br/>Follow‐up: 12 to 24 weeks </p> <p>MCID: 3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −2.41</p> <p>(−4.54 to −0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean score was 12.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.41 lower</b> (4.54 lower to 0.29 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/>Measured by IPSS‐QoL score (range 0 to 6)<br/>Follow‐up: 2 to 6 months </p> <p>MCID: 0.5 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265</p> <p>(2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>1 study reported improvements (P &lt; 0.05), while the other did not.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>Cumulative incidence<br/>Follow‐up: 12 to 48 weeks </p> <p>MCID: relative risk reduction/increase of 0.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.58 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 fewer per 1000</p> <p>(55 fewer to 54 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS</b> : International Prostate Symptom Score; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>QoL</b> : quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to concerns about inconsistency: high statistical inconsistency (I<sup>2</sup> = 67%).<br/><sup>b</sup>Downgraded one level due to imprecision: wide CI including substantial benefit and little to no effect.<br/><sup>c</sup>Downgraded one level due to risk of bias: high risk of bias in included studies.<br/><sup>d</sup>Downgraded one level due to inconsistency: the included studies reported different effects.<br/><sup>e</sup>Downgraded one level due to imprecision: the included studies reported P values, and we are uncertain about effect sizes.<br/><sup>f</sup>Downgraded two levels due to imprecision: CI includes substantial benefits and harms. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001423-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001423-sec-0009"></div> <section id="CD001423-sec-0010"> <h3 class="title" id="CD001423-sec-0010">Description of the condition</h3> <section id="CD001423-sec-0011"> <h4 class="title">Description of the condition</h4> <p>The prostate gland is an organ approximately the size of a walnut located below the urinary bladder encircling the urethra (<a href="./references#CD001423-bbs2-0142" title="LeissnerKH , TisellLE . The weight of the human prostate. Scandinavian Journal of Urology and Nephrology1979;13(2):137-142.">Leissner 1979</a>). Benign prostatic hyperplasia (BPH) is a histological diagnosis defined as an increased number of epithelial and stromal cells in the prostate; this may cause prostatic enlargement and, subsequently, compression of the urethra and obstruction (<a href="./references#CD001423-bbs2-0157" title="RoehrbornCG . Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Reviews in Urology2008;10(1):14-25.">Roehrborn 2008</a>). BPH may therefore develop with or without lower urinary tract symptoms (LUTS) in men aged over 40 years (<a href="./references#CD001423-bbs2-0122" title="DunphyC , LaorL , TeA , KaplanS , ChughtaiB . Relationship between depression and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Reviews in Urology2015;17(2):51-7.">Dunphy 2015</a>). BPH acquires clinical significance when associated with bothersome LUTS (<a href="./references#CD001423-bbs2-0157" title="RoehrbornCG . Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Reviews in Urology2008;10(1):14-25.">Roehrborn 2008</a>). 'Symptom bother' typically correlates with the increased number and severity of symptoms, which relate to both quality of life impairment and treatment seeking (<a href="./references#CD001423-bbs2-0106" title="AgarwalA , EryuzluLN , CartwrightR , ThorlundK , TammelaTL , GuyattGH , et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. European Urology2014;65(6):1211-1217.">Agarwal 2014</a>). Self‐administered questionnaires (e.g. the International Prostate Symptom Score [IPSS]) include the quality of life domain to evaluate the relative degree of bother across all LUTS (<a href="./references#CD001423-bbs2-0107" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker-CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?Journal of Urology1995;154(5):1770-1774.">Barry 1995</a>). Increased LUTS severity is associated with worsening men's overall distress using the man's perception of bladder condition, which is a single‐item global question (ranging from 1 [causes no problems at all] to 6 [causes severe problems]) (<a href="./references#CD001423-bbs2-0111" title="ChappleC , Castro-DiazD , ChuangYC , LeeKS , LiaoL , LiuSP , et al. Prevalence of lower urinary tract symptoms in China, Taiwan, and South Korea: results from a cross-sectional, population-based study. Advances in Therapy2017;34(8):1953-1965.">Chapple 2017</a>). In this Cochrane Review, we consider the term BPH as prostatic enlargement with LUTS to define the disease condition and potential need for intervention. </p> <p>BPH can progress and cause serious consequences such as acute urinary retention, infection, and upper urinary tract deterioration. BPH also negatively impacts public health and a reduction in a person's quality of life (<a href="./references#CD001423-bbs2-0139" title="KozminskiMA , WeiJT , NelsonJ , KentDM . Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU International2015;115(2):308-316.">Kozminski 2015</a>; <a href="./references#CD001423-bbs2-0145" title="MartinS , LangeK , HarenMT , TaylorAW , WittertG . Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. Journal of Urology2014;191(1):130-137.">Martin 2014</a>). In Europe, 30% of men over 50 years of age, equivalent to 26 million men, are affected by bothersome LUTS, including storage symptoms (such as urinary frequency, urgency, and nocturia) or voiding symptoms (such as urinary hesitancy, weak urinary stream, straining to void, and prolonged voiding), or both. The yearly reported associated number of medical prescriptions is estimated to be around 11.6 million for 74 million people at risk from 2004 to 2008 (<a href="./references#CD001423-bbs2-0113" title="CornuJN , CussenotO , HaabF , LukacsB . A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. European Urology2010;58(3):450-456.">Cornu 2010</a>). According to an international study involving 7588 men, the prevalence of LUTS was 18% in 40‐year‐olds, 29% of men in their 50s, 40% of men in their 60s, and 56% of men in their 70s (<a href="./references#CD001423-bbs2-0135" title="HommaY , KawabeK , TsukamotoT , YamanakaH , OkadaK , OkajimaE , et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. International Journal of Urology : Official Journal of the Japanese Urological Association1997;4(1):40-46.">Homma 1997</a>). In the USA, an estimated eight million men over 50 years of age have BPH (<a href="./references#CD001423-bbs2-0157" title="RoehrbornCG . Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Reviews in Urology2008;10(1):14-25.">Roehrborn 2008</a>). More recent data show that the lifetime prevalence of BPH was 26.2% (95% confidence interval 22.8 to 29.6%) (<a href="./references#CD001423-bbs2-0141" title="LeeSW , ChanEM , LaiYK . The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Scientific Reports2017;7(1):7984-7984.">Lee 2017</a>). </p> </section> <section id="CD001423-sec-0012"> <h4 class="title">Diagnosis</h4> <p>Initial evaluation of LUTS suggestive of BPH includes patient history and physical examination, which may include a digital rectal examination, urinalysis, prostate‐specific antigen (PSA), and IPSS (<a href="./references#CD001423-bbs2-0129" title="GravasS , CornuJN , GacciM , GratzkeC , HerrmannTRW , MamoulakisC , et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts (Accessed 7 June 2023)2022.">Gravas 2022</a>; <a href="./references#CD001423-bbs2-0143" title="LernerLB , McVaryKT , BarryMJ , BixlerBR , DahmP , DasAK , et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. Journal of Urology2021;206(4):806-817. [DOI: 10.1097/JU.0000000000002183]">Lerner 2021</a>). A digital rectal examination may be performed to assess the prostate for size and any lesions suspicious of cancer. PSA is secreted by the prostate gland and is found to be abnormally elevated in conditions such as prostate cancer, BPH, infection, or inflammation of the prostate (<a href="./references#CD001423-bbs2-0129" title="GravasS , CornuJN , GacciM , GratzkeC , HerrmannTRW , MamoulakisC , et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts (Accessed 7 June 2023)2022.">Gravas 2022</a>; <a href="./references#CD001423-bbs2-0143" title="LernerLB , McVaryKT , BarryMJ , BixlerBR , DahmP , DasAK , et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. Journal of Urology2021;206(4):806-817. [DOI: 10.1097/JU.0000000000002183]">Lerner 2021</a>). The IPSS is used to assess urinary symptom severity and quality of life. It is also used to document subjective responses to treatment. Measurements of maximum flow rate (Q<sub>max</sub>) and postvoid residual (PVR) are also used in diagnosis and treatment decisions (<a href="./references#CD001423-bbs2-0129" title="GravasS , CornuJN , GacciM , GratzkeC , HerrmannTRW , MamoulakisC , et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts (Accessed 7 June 2023)2022.">Gravas 2022</a>; <a href="./references#CD001423-bbs2-0143" title="LernerLB , McVaryKT , BarryMJ , BixlerBR , DahmP , DasAK , et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. Journal of Urology2021;206(4):806-817. [DOI: 10.1097/JU.0000000000002183]">Lerner 2021</a>). A low Q<sub>max</sub> and a large PVR predict an increased risk of symptom progression (<a href="./references#CD001423-bbs2-0115" title="CrawfordED , WilsonSS , McConnellJD , SlawinKM , LieberMC , SmithJA , et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Journal of Urology2006;175(4):1422-6; discussion 1426-7.">Crawford 2006</a>). Further evaluations may be needed for differential diagnosis or pre‐surgical assessments (<a href="./references#CD001423-bbs2-0129" title="GravasS , CornuJN , GacciM , GratzkeC , HerrmannTRW , MamoulakisC , et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts (Accessed 7 June 2023)2022.">Gravas 2022</a>; <a href="./references#CD001423-bbs2-0143" title="LernerLB , McVaryKT , BarryMJ , BixlerBR , DahmP , DasAK , et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. Journal of Urology2021;206(4):806-817. [DOI: 10.1097/JU.0000000000002183]">Lerner 2021</a>). </p> </section> <section id="CD001423-sec-0013"> <h4 class="title">Treatment</h4> <p>Treatment decisions are based on symptoms and the degree of bother noted by the patient. Initial treatment options for BPH include conservative management (watchful waiting and lifestyle modification) and medication (alpha‐blockers and 5‐alpha reductase inhibitors) (<a href="./references#CD001423-bbs2-0129" title="GravasS , CornuJN , GacciM , GratzkeC , HerrmannTRW , MamoulakisC , et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts (Accessed 7 June 2023)2022.">Gravas 2022</a>; <a href="./references#CD001423-bbs2-0143" title="LernerLB , McVaryKT , BarryMJ , BixlerBR , DahmP , DasAK , et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. Journal of Urology2021;206(4):806-817. [DOI: 10.1097/JU.0000000000002183]">Lerner 2021</a>). If patients have been refractory to conservative and medical treatment, and BPH causes subsequent complications, such as acute urinary retention, recurrent urinary tract infection, bladder stones or diverticula, hematuria, or renal insufficiency, surgical options are considered (<a href="./references#CD001423-bbs2-0129" title="GravasS , CornuJN , GacciM , GratzkeC , HerrmannTRW , MamoulakisC , et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts (Accessed 7 June 2023)2022.">Gravas 2022</a>; <a href="./references#CD001423-bbs2-0143" title="LernerLB , McVaryKT , BarryMJ , BixlerBR , DahmP , DasAK , et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. Journal of Urology2021;206(4):806-817. [DOI: 10.1097/JU.0000000000002183]">Lerner 2021</a>). Currently, guidelines do not recommend the routine use of <i>Serenoa repens</i>, but they state that in instances where patients want to avoid adverse side effects of other treatments, these patients should be informed of its modest benefits (<a href="./references#CD001423-bbs2-0129" title="GravasS , CornuJN , GacciM , GratzkeC , HerrmannTRW , MamoulakisC , et al. EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology. Available at: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts (Accessed 7 June 2023)2022.">Gravas 2022</a>). </p> </section> </section> <section id="CD001423-sec-0014"> <h3 class="title" id="CD001423-sec-0014">Description of the intervention</h3> <p>There are about 30 phytotherapeutic compounds available for the treatment of BPH, and one of the most widely used is an extract from the berry of the American saw palmetto or dwarf palm plant, <i>Serenoa repens</i> , which is also known by its botanical name of <i>Sabal serrulatum</i>. The extracts can be classified as hexane, ethanolic, and supercritical carbon dioxide. The hexane extract (commercially known as Permixon) is proposed to have a higher biological activity and the lowest variability from batch to batch in free fatty acid content, possibly suggesting a higher efficacy and fewer adverse events (<a href="./references#CD001423-bbs2-0132" title="HabibFK , WyllieMG . Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer and Prostatic Diseases2004;7(3):195-200. [DOI: 10.1038/sj.pcan.4500746]">Habib 2004</a>; <a href="./references#CD001423-bbs2-0162" title="ScaglioneF , LuciniV , PannacciM , CaronnoA , LeoneC . Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology2008;82(4):270-5. [DOI: 10.1159/000161128]">Scaglione 2008</a>). </p> <p><i>Serenoa repens</i> is usually taken in a daily dose of 320 mg, although some studies have investigated higher doses (<a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>). The most frequently reported adverse events are minor gastrointestinal symptoms, genitourinary problems, musculoskeletal complaints, and upper respiratory tract infections. </p> </section> <section id="CD001423-sec-0015"> <h3 class="title" id="CD001423-sec-0015">How the intervention might work</h3> <p>The causes of LUTS related to BPH are not entirely known; however, it is theorized that a combination of prostatic cellular proliferation (BPH) and smooth muscle dysfunction are likely reasons (<a href="./references#CD001423-bbs2-0158" title="RoehrbornCG . Chapter 103: Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: PartinAW , PetersCA , KavoussiLR , DmochowskiRR , WeinAJ , editors(s). Campbell Walsh Wein Urology. 13th edition. Elsevier, 2020.">Roehrborn 2020</a>). The purported mechanisms of action for <i>Serenoa repens</i> include: </p> <p> <ul id="CD001423-list-0001"> <li> <p>alteration in cholesterol metabolism (<a href="./references#CD001423-bbs2-0112" title="ChristensenMM , BruskewitzRC . Clinical manifestations of benign prostatic hyperplasia and the indications for therapeutic intervention. Urology Clinics of North America1990;17:509-16. [MEDLINE: 1990327595]">Christensen 1990</a>); </p> </li> <li> <p>antiestrogenic and antiandrogenic effects (<a href="./references#CD001423-bbs2-0121" title="DreikornK , RichterR , SchönhöferPS . Conservative nonhormonal treatment of patients with benign prostatic hyperplasia. Urologe A1990;29(1):8-16. [PMID: 1690486]">Dreikorn 1990</a>; <a href="./references#CD001423-bbs2-0146" title="MarwickC . Growing use of medicinal botanicals forces assessment by drug regulators. JAMA1995;273:607-9. [MEDLINE: 1995147312]">Marwick 1995</a>), with <i>Serenoa repens</i> (Permixon) acting as a weak surrogate 5‐ARI inhibiting the conversion of testosterone to dihydrotestosterone (DHT), <a href="./references#CD001423-bbs2-0117" title="DedhiaRC , McVaryKT . Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. The Journal of Urology2008;179:2119-25.">Dedhia 2008</a>, and the dependent inhibition of 5‐ARI in the stroma and epithelium of the prostate (<a href="./references#CD001423-bbs2-0167" title="WeisserH , TunnS , BehnkeB , KriegM . Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. The Prostate1996;28:300.">Weisser 1996</a>); </p> </li> <li> <p>anti‐inflammatory effects by a decrease in available sex hormone‐binding globulin (<a href="./references#CD001423-bbs2-0119" title="Di SilverioF , FlammiaGP , SciarraA , CaponeraM , MauroM , BuscariniM , et al. Plant extracts in benign prostatic hyperplasia. Minerva Urologica e Nefrologica1993;45:143-9. [MEDLINE: 1994294881]">Di Silverio 1993</a>); </p> </li> <li> <p>pro‐apoptotic properties and inhibition of cellular proliferation (<a href="./references#CD001423-bbs2-0165" title="VacherotF , AzzouzM , Gil-Diez-de-MedinaS , ColombelM , dela TailleA , Lefrere BeldaMA , et al. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon®) in benign prostatic hyperplasia. The Prostate2000;45:507.">Vacherot 2000</a>; <a href="./references#CD001423-bbs2-0071" title="Vela-NavarreteR , Escribano-BurgosM , Lopez FarreA , Garcia-CardosoJ , ManzarbeitiaF , CarrascoC . Serenoa repens treatment modifies BAX/BCL-2 index expression and CASPASE-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. The Journal of Urology2005;173:507-10. Vela-NavarreteR , Garcia CardosoJV , BaratA , ManzarbeitiaF , Lopez FarreA . BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. European Urology2003;44:549-55. ">Vela‐Navarrete 2005</a>); </p> </li> <li> <p>the relaxation of smooth muscles of the detrusor and the prostate via alpha‐1 adrenergic receptors (<a href="./references#CD001423-bbs2-0158" title="RoehrbornCG . Chapter 103: Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: PartinAW , PetersCA , KavoussiLR , DmochowskiRR , WeinAJ , editors(s). Campbell Walsh Wein Urology. 13th edition. Elsevier, 2020.">Roehrborn 2020</a>); </p> </li> <li> <p>placebo effect (<a href="./references#CD001423-bbs2-0158" title="RoehrbornCG . Chapter 103: Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: PartinAW , PetersCA , KavoussiLR , DmochowskiRR , WeinAJ , editors(s). Campbell Walsh Wein Urology. 13th edition. Elsevier, 2020.">Roehrborn 2020</a>). </p> </li> </ul> </p> </section> <section id="CD001423-sec-0016"> <h3 class="title" id="CD001423-sec-0016">Why it is important to do this review</h3> <p>Phytotherapy is widely used for the relief of lower urinary symptoms attributed to BPH. Since the last update (<a href="./references#CD001423-bbs2-0171" title="TacklindJ , MacdonaldR , RutksI , StankeJU , WiltTJ . Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD001423. [DOI: 10.1002/14651858.CD001423.pub3] [PMID: 23235581]">Tacklind 2012</a>), several new trials have been published. Whereas some newer non‐Cochrane reviews have been published, none has included GRADE methods (<a href="./references#CD001423-bbs2-0150" title="NovaraG , GiannariniG , AlcarazA , Cózar-OlmoJM , DescazeaudA , MontorsiF , et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus2016;2(5):553-561.">Novara 2016</a>; <a href="./references#CD001423-bbs2-0159" title="RussoGI , ScanduraC , Di MauroM , CacciamaniG , AlbersenM , HatzichristodoulouG , et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus2021;7(2):420-431.">Russo 2021</a>; <a href="./references#CD001423-bbs2-0166" title="Vela-NavarreteR , AlcarazA , Rodríguez-AntolínA , Miñana LópezB , Fernández-GómezJM , AnguloJC , et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon(®) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int2018;122(6):1049-1065.">Vela‐Navarrete 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001423-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001423-sec-0017"></div> <p>To assess the effects of <i>Serenoa repens</i> in the treatment of men with LUTS consistent with BPH. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001423-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001423-sec-0018"></div> <section id="CD001423-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001423-sec-0020"> <h4 class="title">Types of studies</h4> <p>The methods for this update have been extensively modified since its last publication to meet current methodological expectations; please refer to the <a href="#CD001423-sec-0137">Differences between protocol and review</a> section. We included parallel‐group randomized controlled trials (RCTs). We excluded cluster‐RCTs, as these study designs are not relevant in this setting. We included the first phase of cross‐over studies. We did not include single‐armed studies. We included studies regardless of their publication status or language. </p> </section> <section id="CD001423-sec-0021"> <h4 class="title">Types of participants</h4> <p>We defined the eligible participant population as men over the age of 40 years with a prostate volume of 20 mL or greater (as assessed by ultrasound or cross‐sectional imaging), with lower urinary tract symptoms (LUTS) as determined by International Prostate Symptom Scores (IPSS) of eight or over, and a maximum flow rate (Q<sub>max</sub>) of less than 15 mL/second, as measured by non‐invasive uroflowmetry, invasive pressure flow studies, or both (<a href="./references#CD001423-bbs2-0122" title="DunphyC , LaorL , TeA , KaplanS , ChughtaiB . Relationship between depression and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Reviews in Urology2015;17(2):51-7.">Dunphy 2015</a>; <a href="./references#CD001423-bbs2-0123" title="European Association of Urology. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Amsterdam: European Association of Urology, 2022.">EAU 2022</a>; <a href="./references#CD001423-bbs2-0147" title="McNicholasTA . Benign prostatic hyperplasia and new treatment options—a critical appraisal of the UroLift system. Medical Devices2016;9:115-23.">McNicholas 2016</a>; <a href="./references#CD001423-bbs2-0148" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793-1803.">McVary 2011</a>). We based the age limit on the fact that the prevalence of BPH increases in middle‐aged and older men and is infrequent in younger men (<a href="./references#CD001423-bbs2-0108" title="BarryMJ , FowlerFJ , BinL , PittsJC , HarrisCJ , MulleyAG . The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. Journal of Urology1997;157(1):10-4; discussion 14-5.">Barry 1997</a>; <a href="./references#CD001423-bbs2-0123" title="European Association of Urology. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Amsterdam: European Association of Urology, 2022.">EAU 2022</a>; <a href="./references#CD001423-bbs2-0124" title="EganKB . The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics of North America2016;43(3):289-297.">Egan 2016</a>). We included studies in which only a subset of participants was relevant to this review (i.e. studies in which more than 75% of participants were relevant to this review) if data were available separately for the relevant subset. </p> <p>We excluded studies of men with active urinary tract infection, bacterial prostatitis, chronic renal failure, untreated bladder calculi or large diverticula, prostate cancer, and urethral stricture disease, as well as those who had undergone prior prostate, bladder neck, or urethral surgery. We also excluded studies of people with other conditions that affect urologic symptoms, such as neurogenic bladder due to spinal cord injury, multiple sclerosis, or central nervous system disease. </p> </section> <section id="CD001423-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Experimental intervention</p> <p> <ul id="CD001423-list-0002"> <li> <p><i>Serenoa repens</i> alone (hexanic and non‐hexanic extract) </p> </li> <li> <p><i>Serenoa repens</i> in combination with other phytotherapy </p> </li> </ul> </p> <p>Comparator intervention</p> <p> <ul id="CD001423-list-0003"> <li> <p>Placebo or no intervention</p> </li> </ul> </p> <p>Comparisons</p> <p> <ul id="CD001423-list-0004"> <li> <p><i>Serenoa repens</i> versus placebo or no intervention </p> </li> <li> <p><i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention </p> </li> </ul> </p> <p>To establish fair comparisons, we required that concomitant interventions be the same in the experimental and comparator groups. </p> </section> <section id="CD001423-sec-0023"> <h4 class="title">Types of outcome measures</h4> <p>We did not use measurement of the outcomes assessed in this review as an eligibility criterion. </p> <section id="CD001423-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001423-list-0005"> <li> <p>Urologic symptom scores (continuous outcome)</p> </li> <li> <p>Quality of life (continuous outcome)</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> <section id="CD001423-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p>We did not include secondary outcomes.</p> <section id="CD001423-sec-0026"> <h6 class="title">Method and timing of outcome measurement</h6> <p>We considered the clinically important differences for the review outcome measures to rate the overall certainty of evidence in the summary of findings tables following a minimally contextualized approach (<a href="./references#CD001423-bbs2-0136" title="JaeschkeR , SingerJ , GuyattGH . Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials1989;10(4):407-415.">Jaeschke 1989</a>; <a href="./references#CD001423-bbs2-0137" title="JohnstonBC , PatrickDL , BusseJW , SchünemannHJ , AgarwalA , GuyattGH . Patient-reported outcomes in meta-analyses—Part 1: assessing risk of bias and combining outcomes. Health and Quality of Life Outcomes2013;11:109-109.">Johnston 2013</a>). We considered outcomes measured up to and including 12 months after randomization as short term, and later than 12 months as long term. For adverse events, the timing of outcome assessment was not well‐defined across studies, and outcome data were not disaggregated by follow‐up, so we did not divide them into short and long term. </p> <section id="CD001423-sec-0027"> <p><b>Urologic symptom scores</b></p> <p>Mean change from baseline or final mean value, measured using a validated scale (such as IPSS). We considered the improvement of an IPSS score of three points as the minimal clinically important difference (MCID) to assess the efficacy and comparative effectiveness (<a href="./references#CD001423-bbs2-0107" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker-CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?Journal of Urology1995;154(5):1770-1774.">Barry 1995</a>). If possible, we used different thresholds of MCID based on the severity of IPSS, with a threshold of three points for men with mild LUTS, five for moderate LUTS, and eight for severe LUTS (<a href="./references#CD001423-bbs2-0107" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker-CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?Journal of Urology1995;154(5):1770-1774.">Barry 1995</a>). </p> </section> <section id="CD001423-sec-0028"> <p><b>Quality of life</b></p> <p>Mean change from baseline or final mean value measured as a validated scale (such as IPSS‐quality of life or BPH Impact Index). No threshold has been established for IPSS quality of life in the literature. However, we used an MCID of 0.5 to assess the efficacy and comparative effectiveness. A BPH Impact Index score of one as an MCID was used to indicate improvement (<a href="./references#CD001423-bbs2-0109" title="BarryMJ , CantorA , RoehrbornCG , CAMUSSG. Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. Journal of Urology2013;189(3):987-992.">Barry 2013</a>; <a href="./references#CD001423-bbs2-0126" title="FrancoJV , GaregnaniL , Escobar LiquitayCM , BorofskyM , DahmP . Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2021, Issue 6. Art. No: CD004135. [DOI: 10.1002/14651858.CD004135.pub4] [PMID: PMC8236484]">Franco 2021</a>; <a href="./references#CD001423-bbs2-0155" title="ReesJ . Patients not P values. BJU International2015;115(5):678-679.">Rees 2015</a>). </p> </section> <section id="CD001423-sec-0029"> <p><b>Adverse events</b></p> <p>The number of participants experiencing at least one adverse event (e.g. gastrointestinal discomfort). There were no reported thresholds in adverse events, thus we considered a clinically important difference a risk ratio reduction or increase of at least 25% (<a href="./references#CD001423-bbs2-0131" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-394.">Guyatt 2011</a>). </p> </section> </section> </section> </section> </section> <section id="CD001423-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001423-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database to the date of search with no restrictions on the language of publication: </p> <p> <ul id="CD001423-list-0006"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; <a href="https://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com/</a>) (2022, Issue 9) searched 16 September 2022; </p> </li> <li> <p>MEDLINE (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 16 September 2022); </p> </li> <li> <p>Embase (<a href="https://www.embase.com/" target="_blank">www.embase.com/</a>) from 1974 to 16 September 2022; </p> </li> <li> <p>Scopus (<a href="https://www.scopus.com/home.uri" target="_blank">www.scopus.com/home.uri</a>) from 1966 to 16 September 2022; </p> </li> <li> <p>Science Citation Index Expanded (SCI‐E) Web of Science Clarivate (<a href="https://www.webofscience.com" target="_blank">www.webofscience.com</a>; from 1970 to 16 September 2022); </p> </li> <li> <p>Latin American and Caribbean Literature in Health Sciences (LILACS; <a href="https://lilacs.bvsalud.org/es/" target="_blank">lilacs.bvsalud.org/es/</a>; from 1982 to 16 September 2022); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>) (searched 16 September 2022); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>) (searched 16 September 2022). </p> </li> </ul> </p> <p>Details of the search strategies are provided in <a href="./appendices#CD001423-sec-0097">Appendix 1</a>. </p> </section> <section id="CD001423-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible trials and ancillary publications by searching the reference lists of retrieved included trials, reviews, meta‐analyses, and health technology assessment reports. We contacted the study authors of included trials to identify further studies that we may have missed. We contacted drug/device manufacturers for ongoing or unpublished trials. We searched abstract proceedings of relevant meetings of the American Urological Association, the European Association of Urology, and the International Continence Society from 2020 to 2022 for unpublished studies (see <a href="./appendices#CD001423-sec-0098">Appendix 2</a>). </p> </section> </section> <section id="CD001423-sec-0033"> <h3 class="title" id="CD001423-sec-0033">Data collection and analysis</h3> <section id="CD001423-sec-0034"> <h4 class="title">Selection of studies</h4> <p>We used Covidence to identify and remove potential duplicate records (<a href="./references#CD001423-bbs2-0114" title="Covidence. Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org, Accessed 7 June 2023.">Covidence</a>). Two review authors (out of LT, NJS, GAA, and CF) scanned abstracts, titles, or both to determine which studies should be assessed further using the same software. Two review authors (out of LT, NJS, GAA, and CF) investigated all potentially relevant records as full text, mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies following the criteria for each provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001423-bbs2-0133" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022a</a>). Any discrepancies were resolved through consensus or recourse to a third review author (JVAF or JHJ). We documented the reasons for exclusion of excluded studies. We presented a PRISMA flow diagram showing the process of study selection (<a href="./references#CD001423-bbs2-0151" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71. [DOI: 10.1136/bmj.n71] [PMID: 33782057]">Page 2021</a>). </p> </section> <section id="CD001423-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we pilot‐tested ahead of time. For studies that fulfilled our inclusion criteria, two review authors (out of LT, NJS, GAA, and CF) independently abstracted the following information. </p> <p> <ul id="CD001423-list-0007"> <li> <p>Study design</p> </li> <li> <p>Study dates</p> </li> <li> <p>Study settings and country</p> </li> <li> <p>Participant inclusion and exclusion criteria (e.g. age, baseline IPSS)</p> </li> <li> <p>Participant details, baseline demographics (e.g. age, prostate size, IPSS)</p> </li> <li> <p>Numbers of participants by study and by study arm</p> </li> <li> <p>Details of relevant experimental intervention (e.g. dose, posology, type of <i>Serenoa repens</i> extract) </p> </li> <li> <p>Definitions of relevant outcomes and methods (e.g. type of instrument, such as IPSS) and timing of outcome measurement (e.g. in months), as well as relevant subgroups (e.g. based on age, prostate volume, and the severity of LUTS) </p> </li> <li> <p>Study funding sources</p> </li> <li> <p>Declarations of interest by primary investigators</p> </li> </ul> </p> <p>For dichotomous outcomes, we presented numbers of events and totals for populations in a 2 × 2 table and summary statistics with corresponding measures of variance. We obtained the means and standard deviations or data necessary for continuous outcomes to calculate this information. Any disagreements were resolved by discussion or in consultation with a third review author (JVAF or JHJ) if required. </p> <p>We provided information about potentially relevant studies, including the trial identifiers, in tables. In addition, we contacted the authors of included studies to obtain key missing data as needed. </p> <section id="CD001423-sec-0036"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximized the yield of information by mapping all publications to unique studies and collating all available data. We used the most complete data set aggregated across all known publications. In case of doubt, we prioritized the publication reporting the most extended follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD001423-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (out of LT, NJS, GAA, CF) independently assessed the risk of bias for the results of the main outcomes (those included in the summary of findings table, see below) in each included study using the recently developed revision of the Cochrane risk of bias tool, RoB 2 (<a href="./references#CD001423-bbs2-0125" title="FlemyngE , MooreTH , BoutronI , HigginsJPT , HróbjartssonA , NejstgaardCH , DwanK . Using Risk of Bias 2 to assess results from randomised controlled trials: guidance from Cochrane. BMJ Evidence Based Medicine 24 January 2023 [Epub ahead of print]. [DOI: 10.1136/bmjebm-2022-112102]">Flemyng 2023</a>; <a href="./references#CD001423-bbs2-0134" title="HigginsJPT , SavovićJ , PageMJ , ElbersRG , SterneJAC . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022b</a>). Any disagreements were resolved by discussion or by involving another review author (JVAF). We assessed the risk of bias according to the following domains, focusing on the effect of assignment to the intervention at baseline: </p> <p> <ul id="CD001423-list-0008"> <li> <p>the randomization process;</p> </li> <li> <p>deviations from intended interventions;</p> </li> <li> <p>missing outcome data;</p> </li> <li> <p>measurement of the outcome;</p> </li> <li> <p>selection of the reported results.</p> </li> </ul> </p> <p>Answers to signaling questions and supporting information collectively lead to a domain‐level judgment of 'low risk,' 'some concerns,' or 'high risk' of bias. These domain‐level judgments informed an overall risk of bias judgment for the outcome based on the algorithm in the guidance document of RoB 2. </p> <p>We provided a quote from the study report together with a justification for our judgment in the risk of bias table. We aimed to source published protocols in order to assess selective reporting. Where information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. We made summary assessments of the risk of bias for each important outcome across domains and an overall narrative across studies. </p> <p>We used a Microsoft Excel spreadsheet tool to manage data supporting the answers to the signaling questions and risk of bias judgments (<a href="./references#CD001423-bbs2-0149" title="Microsoft Excel. Microsoft Corporation, 2023. Available from office.microsoft.com/excel.">Microsoft Excel 2023</a>). All of these data are publicly available as supplementary material in the Open Science Framework platform. </p> </section> <section id="CD001423-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MDs) with 95% CIs, unless different studies used different measures to assess the same outcome, in which case we re‐expressed the data as standardized mean differences (SMDs) with 95% CIs. </p> </section> <section id="CD001423-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>Where multiple trial arms were reported in a single trial, we would include only the treatment arms relevant to the review topic. Had two comparisons from the same trial (e.g. drug A versus placebo and drug B versus placebo) been combined in the same meta‐analysis, we would have followed the guidance in Section 6.2 of the <i>Cochrane Handbook</i> (<a href="./references#CD001423-bbs2-0133" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022a</a>). Our preferred approach was to combine groups to create a single pair‐wise comparison. </p> </section> <section id="CD001423-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data where possible (e.g. when a study was available as an abstract only). </p> <p>Where numerical outcome data were missing, such as standard deviations or correlation coefficients, and they could not be obtained from the authors, we calculated them from other available statistics such as 95% CI or P values, according to the methods described in the <i>Cochrane Handbook</i> (<a href="./references#CD001423-bbs2-0133" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022a</a>). If this was not possible, and the missing data could have introduced serious bias, we planned to explore the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> </section> <section id="CD001423-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We identified heterogeneity (inconsistency) through visual inspection of the forest plots to assess the amount of overlap of CIs, and by using the I<sup>2</sup> statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta‐analysis. We interpreted the I<sup>2</sup> statistic as follows (<a href="./references#CD001423-bbs2-0118" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Deeks 2022</a>): </p> <p> <ul id="CD001423-list-0009"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>In the case of heterogeneity, we attempted to identify possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD001423-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess selective outcome reporting. When we included 10 or more studies in a meta‐analysis, we used funnel plots to assess small‐study effects (<a href="./references#CD001423-bbs2-0152" title="PageMJ , HigginsJPT , SterneJAC . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Page 2022</a>). Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to study size, poor methodological design (and hence bias of small studies), and publication bias. We therefore used caution in our interpretation of results. </p> </section> <section id="CD001423-sec-0043"> <h4 class="title">Data synthesis</h4> <p>Unless there was good evidence for homogeneous effects across studies, we summarized data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. We also performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook</i> (<a href="./references#CD001423-bbs2-0133" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Higgins 2022a</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method. For continuous outcomes, we used the inverse variance method. We used Review Manager Web software to perform the analyses (<a href="./references#CD001423-bbs2-0156" title="Review Manager Web (RevMan Web). Version 4.3. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). </p> </section> <section id="CD001423-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to potentially introduce clinical heterogeneity, and carried out subgroup analyses to investigate interactions. </p> <p> <ul id="CD001423-list-0010"> <li> <p>Type of <i>Serenoa repens</i> preparation (hexanic versus non‐hexanic extract) </p> </li> <li> <p>Participant age (less than 65 years versus 65 years or more)</p> </li> <li> <p>Severity of LUTS based on IPSS (score less than or equal to 19 [moderately symptomatic] versus greater than 19 [severely symptomatic]) </p> </li> </ul> </p> <p>These subgroup analyses are based on the following observations.</p> <p> <ul id="CD001423-list-0011"> <li> <p>Other reviews highlight that there might be different effects of different <i>Serenoa repens</i> extracts (<a href="./references#CD001423-bbs2-0159" title="RussoGI , ScanduraC , Di MauroM , CacciamaniG , AlbersenM , HatzichristodoulouG , et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus2021;7(2):420-431.">Russo 2021</a>). </p> </li> <li> <p>Age is a well‐known risk factor for BPH surgery. Older men have a higher rate of postoperative complications compared with younger men (<a href="./references#CD001423-bbs2-0110" title="BhojaniN , GandagliaG , SoodA , RaiA , PucherilD , ChangSL , et al. Morbidity and mortality after benign prostatic hyperplasia surgery: data from the American College of Surgeons national surgical quality improvement program. Journal of Endourology2014;28(7):831-840.">Bhojani 2014</a>; <a href="./references#CD001423-bbs2-0153" title="PariserJJ , PearceSM , PatelSG , BalesGT . National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology2015;86(4):721-725.">Pariser 2015</a>). The age cut‐off is based on the World Health Organization's (WHO) definition of old age (<a href="./references#CD001423-bbs2-0168" title="World Health Organization. Proposed working definition of an older person in Africa for the MDS project.  www.who.int/healthinfo/survey/ageingdefnolder/en (accessed 17 August 2017).">WHO 2002</a>). </p> </li> <li> <p>The relationship between changes in IPSS scores and patient global ratings of improvement is influenced by the baseline scores (<a href="./references#CD001423-bbs2-0107" title="BarryMJ , WillifordWO , ChangY , MachiM , JonesKM , Walker-CorkeryE , et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?Journal of Urology1995;154(5):1770-1774.">Barry 1995</a>). </p> </li> </ul> </p> </section> <section id="CD001423-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the influence of the following factors (when applicable) on effect size: </p> <p> <ul id="CD001423-list-0012"> <li> <p>restricting the analysis to RCTs by considering risk of bias, restricting to studies with an overall low risk of bias. </p> </li> </ul> </p> <p>If the sensitivity analyses provided moderate‐ to high‐certainty evidence, we would draw our main conclusions (summary of findings tables) based on this estimate. This is a similar approach to the previous version of this review (<a href="./references#CD001423-bbs2-0171" title="TacklindJ , MacdonaldR , RutksI , StankeJU , WiltTJ . Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD001423. [DOI: 10.1002/14651858.CD001423.pub3] [PMID: 23235581]">Tacklind 2012</a>). </p> </section> <section id="CD001423-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach (<a href="./references#CD001423-bbs2-0130" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck-YtterY , SchünemannHJ . What is "quality of evidence" and why is it important to clinicians?BMJ (Clinical Research Ed.)2008;336(7651):995-998.'>Guyatt 2008</a>). For each comparison, two review authors (JVAF and LT) independently rated the certainty of the evidence for each outcome as 'high,' 'moderate,' 'low,' or 'very low,' using <a href="./references#CD001423-bbs2-0128" title="GRADEpro GDT. Hamilton (ON): McMaster University and Evidence Prime, Date accessed 7 June 2023. Available at gradepro.org.">GRADEpro GDT</a> software (<a href="./references#CD001423-bbs2-0128" title="GRADEpro GDT. Hamilton (ON): McMaster University and Evidence Prime, Date accessed 7 June 2023. Available at gradepro.org.">GRADEpro GDT</a>). Any discrepancies were resolved by consensus or if needed by arbitration from a third review author (JHJ). For each comparison, we presented a summary of the evidence for the main outcomes in the summary of findings table, which provides key information about the best estimate of the magnitude of effect in relative terms and absolute differences for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of our overall confidence in the effect estimates for each outcome (<a href="./references#CD001423-bbs2-0164" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>). </p> <p>We considered five criteria, not only related to internal validity (overall risk of bias, inconsistency, imprecision, and publication bias) but also external validity (directness of results), for downgrading the certainty of the evidence for a specific outcome (<a href="./references#CD001423-bbs2-0164" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Schünemann 2022</a>). We included the following comparisons. </p> <p> <ul id="CD001423-list-0013"> <li> <p><i>Serenoa repens</i> versus placebo or no intervention </p> </li> <li> <p><i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention </p> </li> </ul> </p> <p>Each summary of findings table includes the following outcomes.</p> <p> <ul id="CD001423-list-0014"> <li> <p>Urologic symptom scores</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> <p>We followed GRADE guidance for detailed footnotes and language to describe the certainty of the evidence (<a href="./references#CD001423-bbs2-0160" title="SantessoN , Carrasco-LabraA , LangendamM , Brignardello-PetersenR , MustafaRA , HeusP , et al. Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. J Clin Epidemiol2016;74:28-39. [DOI: 10.1016/j.jclinepi.2015.12.006] [PMID: 26796947]">Santesso 2016</a>; <a href="./references#CD001423-bbs2-0161" title="SantessoN , GlentonC , DahmP , GarnerP , AklEA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol2020;119:126-135. [DOI: 10.1016/j.jclinepi.2019.10.014] [PMID: 31711912]">Santesso 2020</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001423-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001423-sec-0047"></div> <section id="CD001423-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD001423-sec-0049"> <h4 class="title">Results of the search</h4> <p>For this update, we narrowed the focus of the review questions, focusing on the effects of <i>Serenoa repens</i> versus placebo or in combination with other psychotherapeutic agents versus placebo. As a result, we excluded 7 of 32 studies included in the previous update because they were not included in this focused review question (<a href="./references#CD001423-bbs2-0035" title="BraeckmanJ , BruhwylerJ , VanderkerckhoveK , GéczyJ . Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytotherapy Research1997;1:558-63. BraeckmanJ , DenisL , deLevalJ , KeuppensF , CornetA , De Bruyne, et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. European Journal of Clinical Research1997;9:247-59. BraeckmanJ . The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Current Therapeutic Research1994;55(7):776-85. ">Braeckman 1997</a>; <a href="./references#CD001423-bbs2-0037" title="CarraroJC , RaynaudJP , KochG , ChisholmGD , Di SilverioF , TeillacP , et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. The Prostate1996;29(4):231-40. [MEDLINE: 1997030765]CarraroJC , RaynaudJP , KochG , ChisholmGD , Di SilverioF , TeiucicP , et al. Extract of saw palmetto for treatment of symptomatic benign prostatic hyperplasia. Integrative Medicine1998;1(1):39-40. ">Carraro 1996</a>; <a href="./references#CD001423-bbs2-0041" title="DebruyneF , BoyleP , Calais Da SilvaF , GillenwaterJG , HamdyFC , PerrinP , et al. Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients—PERMAL study subset analysis [Evaluation du benefice clinique de Permixon® et de la tamsulosine dans le traitement de l'hypertrophie bénigne de la prostate (HBP) sévére: Analyse d'une sous-groupe de l'étude Permal]. European Urology2004;45:773-80. DebruyneF , BoyleP , Da SilvaFC , GillenwaterJG , HamdyFC , PerrinP , et al. Evaluation of the clinical benefit of permixon((R)) and tamsulosin in severe BPH patients—PERMAL study subset analysis. PROGRES EN UROLOGIE2004;14(3):326-331. DebruyneF , KochG , BoyleP , Da SilvaFC , GillenwaterJG , HamdyFC , et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study [Comparaison d'un produit de phytotherapie (Permixon) et d'un alpha-bloquant (tamsulosine) dans le traitement de l'hypertrophie benigne de la prostate: etude internationale randomisee d'une duree de 12 mois]. Progres en Urologie2002;12(3):384-94. DebruyneF , KochG , Da SilvaFC , GillenwaterJG , HamdyFC , PerrinP , et al. Comparison of a phytotherapeutic agent (Permixon®) with an a-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study [Comparaison d'un produit de phytothérapie (Permixon®) et d'un alpha-bloquant (tamsulosine) dans le traitement de l'hypertrophie bénigne de la prostate: étude internationale randomisée d'une durée de 12 mois]. Progrès en Urologie2002;41:497-507. ">Debruyne 2002</a>; <a href="./references#CD001423-bbs2-0045" title="EngelmannU , WaltherC , BondarenkoB , FunkP , SchläfkeS . Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittel-Forschung2006;56(3):222-9. ">Engelmann 2006</a>; <a href="./references#CD001423-bbs2-0059" title="PannunzioE , DascenzoR , GiardinettiF , CiviliP , PersichelliE . Serenoa repens in the treatment of human benign prostatic hyperplasia (BPH). Journal of Urology1987;137(4):A226-A226. PannunzioE , D’AscenzoR , GiardinettiF , CiviliP , PersichelliE . Serenoa repens vs. Gestorone caproate in the treatment of benign prostatic hypertension: a randomized study [Serenoa repens vs. gestonorone caproato nel trattamento dell’ipertofia prostatica benigna: Studio randomizzato]. Urologia1986;53(5):696-705. ">Pannunzio 1986</a>; <a href="./references#CD001423-bbs2-0064" title="RovedaS , ColomboP . Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160 mg or rectal capsules 640 mg [Sperimentazione clinica controllata sulla bioequivalenza terapeutica e sulla tollerabilita dei prodotti a base di Serenoa repens in capsule da 160 mg o capsule rettali da 640 mg]. Archivio di Medicina Interna1994;46(2):61-75. ">Roveda 1994</a>; <a href="./references#CD001423-bbs2-0066" title="SökelandJ , AlbrechtJ . Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome [Kombination aus Sabal- und Urticaestrakt vs. finasterid bei BPH (Stad. I bis II nach Alken); Vergleich der therapeutischen wirksamkeit in einer einjahrigen doppelblindstudie]. Urologe A1997;36(4):327-33. [MEDLINE: 1997419443]SökelandJ , WaltherC . A combination preparation of sabal and urtica extract versus finasteride in benign prostatic hyperplasia (BPH)—an analysis of data regarding prostatic volume and treatment success. Zeitschrift fur Phytotherapie2000;21(6):299-305. SökelandJ . Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. British Journal of Urology International2000;86:439-42. ">Sökeland 1997</a>), and moved another 7 older studies to awaiting classification because of missing full text (see <a href="./references#CD001423-sec-0142" title="">Characteristics of studies awaiting classification</a>) (<a href="./references#CD001423-bbs2-0082" title="CukierJ , DucassouJ , Le GuillouM , LericheA , LobelB , ToubolJ . Permixon versus placebo; results of a multicenter study [Permixon versus placebo; resultats d'une étude multicentrique]. Comptes Rendus de Therapeutique et de Pharmacologie Clinique1985;4:15-21. ">Cukier 1985</a>; <a href="./references#CD001423-bbs2-0085" title="EmiliE , Lo CignoM , PetroneU . Clinical results on a new drug in the therapy of prostate hypertrophy (Permixon) [Risultati clinici su un nuovo farmaco nella terapia dell'ipertofia della prostata (Permixon)]. Urologia1983;50:1042-8. ">Emili 1983</a>; <a href="./references#CD001423-bbs2-0087" title="GabricV , MiskicH . Treatment of benign prostate adenoma and chronic prostatitis [Behandlung des benignen prostata-adenoms und der chronischen prostatatitis]. Therapiewoche1987;37:1775-88. ">Gabric 1987</a>; <a href="./references#CD001423-bbs2-0089" title="LöbelenzJ . Extractum Sabal fructus in benign prostatic hyperplasia (BPH). Stage I and II clinical trial [Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). Klinische prufung im stadium I und II]. Therapeutikon1992;6(1-2):34-7. ">Löbelenz 1992</a>; <a href="./references#CD001423-bbs2-0091" title="MatteiFM , CaponeM , AcconciaA . Drug therapy of benign prostatic hyperplasia with saw palmetto extract [Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme]. TW Urologie Nephrologie1990;2:346-50. MatteiFM , CaponeM , AcconciaA . Liposterolic extract of Serenoa Repens in management of benign prostatic hypertrophy. Urologia1988;55(5):547-552. ">Mattei 1990</a>; <a href="./references#CD001423-bbs2-0092" title="MohantyNK , JhaRJ , DuttC . Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic Grade I to Grade II benign prostatic hyperplasia (PBH). Indian Journal of Urology1999;16(1):26-31. MohantyNK . Serenoa repens versus placebo in management of benign prostatic hyperplasia (bph)—a randomised double blind control clinical trial. Nephrology, urology, transplantation society of SAARC, Sri Lanka1999:137. ">Mohanty 1999</a>; <a href="./references#CD001423-bbs2-0096" title="TascaA , BarulliM , CavazzanaA , ZattoniF , ArtibaniW , PaganoF . Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs placebo [Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo]. Minerva Urologica e Nefrologica1985;37:87-91. [PMID: 2413558]TascaA , BarulliM , CavazzanaA , ZattoniF , ArtibaniW , PaganoF . Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo [Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo]. Minerva Urologica e Nefrologica1985;37:87-91. [MEDLINE: 1986019370]">Tasca 1985</a>). A total of 18 studies from the previous version of this review were relevant to our review question. </p> <p>We conducted a de novo search and identified 14,362 records from electronic databases. We found no relevant records in additional sources. After removing duplicates, we screened the titles and abstracts of the remaining 6957 records, of which 6870 were excluded. We assessed 87 full‐text articles and excluded 49 records for various reasons (see <a href="#CD001423-sec-0056">Excluded studies</a>). We identified nine new studies through this search (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>; <a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>; <a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a>; <a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>; <a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a>; <a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>). Considering the 18 relevant studies from the previous version of the review, we included 27 studies with 4656 participants in this update. A PRISMA flow diagram illustrating the flow of literature through the assessment process is presented in <a href="#CD001423-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD001423-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001423-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001423-sec-0050"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD001423-sec-0140" title="">Characteristics of included studies</a> and <a href="#CD001423-tbl-0003">Table 1</a>. </p> <div class="table" id="CD001423-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Brand and daily dosage (when available)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Co‐intervention</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Age mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>IPSS mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Prostate volume mean (SD)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>C</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Studies comparing <i>Serenoa repens</i> with placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serbia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostamol Uno 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.9 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 (3.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2 (4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 (11.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 to 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg daily</p> <p>Prostamol Uno 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.61 (7.69)</p> <p>65.14 (7.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.14 (7.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prosta Urgenin Uno 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.25 (8.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.7 (8.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.42 (4.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.69 (4.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Talso Uno 320 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>66.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbon dioxide extract 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9 (8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7 (5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.7 (13.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.9 (15.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0006" title="BoccafoschiC , AnnosciaS . Serenoa repens extract and placebo in prostatic benign hyperplasia: clinical results [Confronto fra estratto di serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica]. Urologia1983;50:1257-68. [DOI: 10.1177/039156038305000615]">Boccafoschi 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (55 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (54 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0008" title="ChampaultG , PatelJC , BonnardAM . A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. British Journal of Clinical Pharmacology1984;18:461-2. [DOI: 10.1111/j.1365-2125.1984.tb02491.x] [MEDLINE: 1985023088]">Champault 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0010" title="DescotesJL , RambeaudJJ , DeschaseauxP , FaureG . Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation1995;5:291-7. ">Descotes 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.6 (8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 to 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SR 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 (± 9.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.3 (± 9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.7 (± 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8 (± 4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.2 (7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.4 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2 (5.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3 (5.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.8 (16.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 (15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.2 (6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.9 (5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 (3.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 (11.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SR 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0017" title="MandressiS , TaralloU , MaggioniA , TomboliniP , RoccoF , Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon®) compared to that of the extract of Pygeum africanum and a placebo [Terapia medica dell'adenoma prostatico: confronto della efficacia dell'estratto di serenoa repens (Permixon®) versus l'estratto di pigeum africanum e placebo]. Urologia1983;50(4):752-8. ">Mandressi 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0022" title="Reece SmithH , MemonA , SmartCJ , DewburyK . The value of Permixon in benign prostatic hypertrophy. British Journal of Urology1986;58:36-40. ">Reece Smith 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.15 (5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.03 (6.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.5 (1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.4 (1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 (0.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.1 (0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.2 (0.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostataplex (dosing not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VISPO/SPO 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.76 (7.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.18 (8.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.00 (4.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.00 (3.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 to 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbon dioxide extract 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1 (1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.9 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014 to 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SR 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.47 (5.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.32 (5.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.42 (3.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.34 (4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.0 (19.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.3 (25.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Studies comparing phytotherapy containing <i>Serenoa repens</i> with placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden/Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curbicin</p> <p>(PSO 480 mg + SR 480 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 (6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 (5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ProstateEZE Max</p> <p>(PSO 160 mg, epilobium 500 mg, lycopene 2.1 mg, pygeum 15 g + SR 660 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (10.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9 (9.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tradamixina</p> <p>(<i>Eisenia</i> 80 mg, <i>Tribulus</i> 100 mg, chitosan oligosaccharide (Biovis) 100 mg + SR 320 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>64.2 (8.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 (5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 to 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO 160/120</p> <p>(Sabal‐Urtica 240 mg + SR 320 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 (3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.8 (3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.5 (17.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.8 (17.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 to 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nettle root 240 mg, PSO 480 mg, lemon 99 mg, vitamin A 570 IU + SR 318 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.1 (8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9 (9.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1 (7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.5 (29.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.6 (26.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostagutt forte</p> <p>(Sabal‐Urtica 240 mg + SR 320 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Profluss</p> <p>(selenium and lycopene + SR 320 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0021" title="PreussHG , MarcusenC , ReganJ , KlimbergIW , WelebirTA , JonesWA . Randomized trial of a combination of natural products (Cernitin, saw palmetto, beta-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology2001;33:217-25. ">Preuss 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cernitin AF</p> <p>(Cernitin 378 mg, vitamin E 100 IU + SR with beta‐sitosterol 286 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>(*) Hexanic extract of <i>Serenoa repens</i>; <b>C</b> : control; <b>I</b> : intervention; <b>IPSS</b> : International Prostate Symptom Score; <b>IU</b> : international units; <b>N/A</b> : not available (not described); <b>PSO</b> : pumpkin seed oil; <b>SR</b>: <i>Serenoa repens;</i><b>SD</b>: standard deviation </p> </div> </div> <section id="CD001423-sec-0051"> <h5 class="title">Study design and settings</h5> <p>All studies were RCTs. The median sample size was 100 participants (interquartile range 61 to 212), and the median follow‐up was 24 weeks (interquartile range 12 to 52). Studies were conducted in Serbia (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>), the USA (<a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>; <a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>; <a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a>; <a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a>; <a href="./references#CD001423-bbs2-0021" title="PreussHG , MarcusenC , ReganJ , KlimbergIW , WelebirTA , JonesWA . Randomized trial of a combination of natural products (Cernitin, saw palmetto, beta-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology2001;33:217-25. ">Preuss 2001</a>), Germany (<a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>; <a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a>), Italy (<a href="./references#CD001423-bbs2-0006" title="BoccafoschiC , AnnosciaS . Serenoa repens extract and placebo in prostatic benign hyperplasia: clinical results [Confronto fra estratto di serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica]. Urologia1983;50:1257-68. [DOI: 10.1177/039156038305000615]">Boccafoschi 1983</a>; <a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a>; <a href="./references#CD001423-bbs2-0017" title="MandressiS , TaralloU , MaggioniA , TomboliniP , RoccoF , Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon®) compared to that of the extract of Pygeum africanum and a placebo [Terapia medica dell'adenoma prostatico: confronto della efficacia dell'estratto di serenoa repens (Permixon®) versus l'estratto di pigeum africanum e placebo]. Urologia1983;50(4):752-8. ">Mandressi 1983</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>), France (<a href="./references#CD001423-bbs2-0008" title="ChampaultG , PatelJC , BonnardAM . A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. British Journal of Clinical Pharmacology1984;18:461-2. [DOI: 10.1111/j.1365-2125.1984.tb02491.x] [MEDLINE: 1985023088]">Champault 1984</a>; <a href="./references#CD001423-bbs2-0010" title="DescotesJL , RambeaudJJ , DeschaseauxP , FaureG . Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation1995;5:291-7. ">Descotes 1995</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>), Turkey (<a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>), Korea (<a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>), the UK (<a href="./references#CD001423-bbs2-0022" title="Reece SmithH , MemonA , SmartCJ , DewburyK . The value of Permixon in benign prostatic hypertrophy. British Journal of Urology1986;58:36-40. ">Reece Smith 1986</a>), China (<a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>), India (<a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>), Sweden (<a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a>), Australia (<a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>; <a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a>), and Russia (<a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a>), and one study was conducted in more than one country (<a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>). </p> </section> <section id="CD001423-sec-0052"> <h5 class="title">Participants</h5> <p>Most studies included men aged &gt; 50 (mean age range 52 to 68), and a few studies included men with a mean age &gt; 65 (<a href="./references#CD001423-bbs2-0006" title="BoccafoschiC , AnnosciaS . Serenoa repens extract and placebo in prostatic benign hyperplasia: clinical results [Confronto fra estratto di serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica]. Urologia1983;50:1257-68. [DOI: 10.1177/039156038305000615]">Boccafoschi 1983</a>; <a href="./references#CD001423-bbs2-0010" title="DescotesJL , RambeaudJJ , DeschaseauxP , FaureG . Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation1995;5:291-7. ">Descotes 1995</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a>; <a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a>; <a href="./references#CD001423-bbs2-0022" title="Reece SmithH , MemonA , SmartCJ , DewburyK . The value of Permixon in benign prostatic hypertrophy. British Journal of Urology1986;58:36-40. ">Reece Smith 1986</a>). Most studies included men with moderate urologic symptoms (IPSS range 8 to 19), with only three studies including a mean score of 20 or more (<a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>). Less than half of the studies reported prostate size, which was mostly small to moderate size (mean size range 26.1 to 58.5 mL) (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>; <a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>; <a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a>; <a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a>; <a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>; <a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>). </p> </section> <section id="CD001423-sec-0053"> <h5 class="title">Interventions and comparisons</h5> <p>We included 27 studies for the following comparisons.</p> <p> <ul id="CD001423-list-0015"> <li> <p><i>Serenoa repens</i> versus placebo (19 studies) </p> <ul id="CD001423-list-0016"> <li> <p>Nine studies included the hexanic extract of <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>; <a href="./references#CD001423-bbs2-0006" title="BoccafoschiC , AnnosciaS . Serenoa repens extract and placebo in prostatic benign hyperplasia: clinical results [Confronto fra estratto di serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica]. Urologia1983;50:1257-68. [DOI: 10.1177/039156038305000615]">Boccafoschi 1983</a>; <a href="./references#CD001423-bbs2-0008" title="ChampaultG , PatelJC , BonnardAM . A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. British Journal of Clinical Pharmacology1984;18:461-2. [DOI: 10.1111/j.1365-2125.1984.tb02491.x] [MEDLINE: 1985023088]">Champault 1984</a>; <a href="./references#CD001423-bbs2-0010" title="DescotesJL , RambeaudJJ , DeschaseauxP , FaureG . Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation1995;5:291-7. ">Descotes 1995</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0017" title="MandressiS , TaralloU , MaggioniA , TomboliniP , RoccoF , Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon®) compared to that of the extract of Pygeum africanum and a placebo [Terapia medica dell'adenoma prostatico: confronto della efficacia dell'estratto di serenoa repens (Permixon®) versus l'estratto di pigeum africanum e placebo]. Urologia1983;50(4):752-8. ">Mandressi 1983</a>; <a href="./references#CD001423-bbs2-0022" title="Reece SmithH , MemonA , SmartCJ , DewburyK . The value of Permixon in benign prostatic hypertrophy. British Journal of Urology1986;58:36-40. ">Reece Smith 1986</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>). </p> </li> <li> <p>The other studies included other formulations: Prostamol Uno (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>, <a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>), Prosta‐Urgenin Uno (<a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>), Talso Uno (<a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>), carbon dioxide extract (<a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>; <a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a>), Prostablex (<a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a>), VISPO/SPO (<a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>), or other unspecified compounds of <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a>; <a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>). </p> </li> </ul> </li> <li> <p>Phytotherapy containing <i>Serenoa repens</i> versus placebo (8 studies) </p> <ul id="CD001423-list-0017"> <li> <p>Curbicin: pumpkin seed oil and <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a>) </p> </li> <li> <p>ProstaEZE Max: pumpkin seed oil, <i>Epilobium</i> , lycopene, pygeum, and <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>) </p> </li> <li> <p>Tradaximina: <i>Eisenia</i> , <i>Tribulus</i> , chitosan oligosaccharide (Biovis), and <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a>) </p> </li> <li> <p>PRO 160/120: sabal urtica and <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a>) </p> </li> <li> <p>Lipoidal extract of <i>Serenoa repens</i> with other phytotherapeutics (<a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a>) </p> </li> <li> <p>Prostagutt forte: sabal urtica and <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a>) </p> </li> <li> <p>Profluss: selenium, lycopene, and <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>) </p> </li> <li> <p>Cernitin AF: Cernitin, B‐sitoesterol, vitamin E, and <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0021" title="PreussHG , MarcusenC , ReganJ , KlimbergIW , WelebirTA , JonesWA . Randomized trial of a combination of natural products (Cernitin, saw palmetto, beta-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology2001;33:217-25. ">Preuss 2001</a>) </p> </li> </ul> </li> </ul> </p> <p>The most commonly used daily dose was 320 mg daily, either as a single dose or 160 mg twice daily. For the comparisons to placebo, one study did not specify the dosing (<a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a>), and one study used a 200 mg extract twice daily (400 mg daily total; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>). Whereas the doses of <i>Serenoa repens</i> in combined treatment with another phototherapy usually ranged from 286 to 320, one study included a higher dose of 480 mg daily (<a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a>). </p> <p>Co‐interventions were described in five studies, and in all cases included tamsulosin (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>). </p> </section> <section id="CD001423-sec-0054"> <h5 class="title">Outcomes</h5> <p>Twenty‐one studies reported data on urologic symptoms (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>; <a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>; <a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>; <a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>; <a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>; <a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>; <a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a>; <a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a>; <a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a>; <a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a>; <a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0021" title="PreussHG , MarcusenC , ReganJ , KlimbergIW , WelebirTA , JonesWA . Randomized trial of a combination of natural products (Cernitin, saw palmetto, beta-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology2001;33:217-25. ">Preuss 2001</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>; <a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a>; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>; <a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>), but only a subset of 12 of these studies reported data on quality of life (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>; <a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>; <a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>; <a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a>; <a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>; <a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>). Twenty‐four studies reported data on adverse events (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>; <a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>; <a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>; <a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>; <a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>; <a href="./references#CD001423-bbs2-0006" title="BoccafoschiC , AnnosciaS . Serenoa repens extract and placebo in prostatic benign hyperplasia: clinical results [Confronto fra estratto di serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica]. Urologia1983;50:1257-68. [DOI: 10.1177/039156038305000615]">Boccafoschi 1983</a>; <a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a>; <a href="./references#CD001423-bbs2-0008" title="ChampaultG , PatelJC , BonnardAM . A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. British Journal of Clinical Pharmacology1984;18:461-2. [DOI: 10.1111/j.1365-2125.1984.tb02491.x] [MEDLINE: 1985023088]">Champault 1984</a>; <a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>; <a href="./references#CD001423-bbs2-0010" title="DescotesJL , RambeaudJJ , DeschaseauxP , FaureG . Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation1995;5:291-7. ">Descotes 1995</a>; <a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a>; <a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a>; <a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0021" title="PreussHG , MarcusenC , ReganJ , KlimbergIW , WelebirTA , JonesWA . Randomized trial of a combination of natural products (Cernitin, saw palmetto, beta-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology2001;33:217-25. ">Preuss 2001</a>; <a href="./references#CD001423-bbs2-0022" title="Reece SmithH , MemonA , SmartCJ , DewburyK . The value of Permixon in benign prostatic hypertrophy. British Journal of Urology1986;58:36-40. ">Reece Smith 1986</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>; <a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a>; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>; <a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>). One study did not report any outcomes relevant to this review (<a href="./references#CD001423-bbs2-0017" title="MandressiS , TaralloU , MaggioniA , TomboliniP , RoccoF , Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon®) compared to that of the extract of Pygeum africanum and a placebo [Terapia medica dell'adenoma prostatico: confronto della efficacia dell'estratto di serenoa repens (Permixon®) versus l'estratto di pigeum africanum e placebo]. Urologia1983;50(4):752-8. ">Mandressi 1983</a>). </p> </section> <section id="CD001423-sec-0055"> <h5 class="title">Funding sources</h5> <p>Ten studies were funded by the pharmaceutical industry (<a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>; <a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>; <a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a>; <a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a>; <a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0021" title="PreussHG , MarcusenC , ReganJ , KlimbergIW , WelebirTA , JonesWA . Randomized trial of a combination of natural products (Cernitin, saw palmetto, beta-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology2001;33:217-25. ">Preuss 2001</a>; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>; <a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a>; <a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>); two studies were funded by government agencies (<a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>; <a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>); and the remaining studies did not specify funding sources. </p> </section> </section> <section id="CD001423-sec-0056"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD001423-sec-0141" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 49 studies for the following reasons.</p> <p> <ul id="CD001423-list-0018"> <li> <p>Sixteen studies were non‐randomized studies or had no control group (<a href="./references#CD001423-bbs2-0032" title="Al-ShukriSH , DeschaseauxP , KuzminIV . Early urodynamic effects of the lipido-sterolic extract of Serenoa repens (Permixon®) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases2000;3:195-9. ">Al‐Shukri 2000</a>; <a href="./references#CD001423-bbs2-0029" title="AlcarazA , GacciM , FicarraV , Medina-PoloJ , SaloniaA , Fernández-Gómez JM et al. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study. Journal of Clinical Medicine2022;11(4):967. AlcarazA , Rodríguez-AntolínA , Carballido-RodríguezJ , Castro-DíazD , Esteban-FuertesM , Cózar-OlmoJM , et al. Clinical benefit of tamsulosin and the hexanic extract of serenoa repens, in combination or as monotherapy, in patients with moderate/severe luts-bph: A subset analysis of the qualiprost study. Journal of Clinical Medicine2020;9(9):1-14. ">Alcaraz 2022</a>; <a href="./references#CD001423-bbs2-0033" title="AuthiéD , CauquilJ . Appreciation of the efficacy of Permixon in daily practice: multicenter study [Appréciation de l'efficacité de Permixon en pratique quotidienne: étude multicentrique]. Comptes Rendus de Thérapeutique et de Pharmacologie Clinique1987;5(56):4-13. ">Authié 1987</a>; <a href="./references#CD001423-bbs2-0042" title="Di MaidaF , MariA , RubinoR , MinerviniA , CariniM , SienaG . A Prospective, Open-Label Comparison of Tamsulosin plus Serenoa repens and Bovine Colostrum versus Tamsulosin Alone in the Treatment of Benign Prostatic Hyperplasia. Urologia Internationalis2020;104(5-6):351-355. ">Di Maida 2020</a>; <a href="./references#CD001423-bbs2-0047" title="GerberGS , ZagajaGP , BalesGT , ChodakGW , ContrerasBA . Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology1998;51(6):1003-7. ">Gerber 1998</a>; <a href="./references#CD001423-bbs2-0048" title="GiannakopoulosX , BaltogiannisD , GiannakisD , TasosA , SofikitisN , CharalabopoulosK , et al. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. Advances in Natural Therapy2002;19(2):285-96. ">Giannakopoulos 2002</a>; <a href="./references#CD001423-bbs2-0049" title="GiulianelliR , PecoraroS , SepeG , LeonardiR , GentileBC , AlbanesiL , et al. Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation. Archivio Italiano di Urologia e Andrologia2012;84(2):94-98. ">Giulianelli 2012</a>; <a href="./references#CD001423-bbs2-0051" title="GurzhenkoI , SpyrydonenkoV . Improvement of sexual functions in men with benign prostatic hyperplasia with long-term use of the Serenoa repens extract. Journal of Sexual Medicine2020;17(6):S160-S161. ">Gurzhenko 2020</a>; <a href="./references#CD001423-bbs2-0054" title="JuX , GuX , ZhangZ , WeiZ , XuZ , MiaoH , et al. Efficacy and safety of Saw Palmetto Extract Capsules in the treatment of benign prostatic hyperplasia. Zhonghua nan ke xue [National journal of andrology]2015;21(12):1098-1101. ">Ju 2015</a>: <a href="./references#CD001423-bbs2-0060" title="PavoneC , AbbadessaD , TaraintinoML , OxeniusI , LaganàA , LupoA , et al. Association of Serenoa repens, Urtica dioica and Pinus pinaster. Safety and efficacy in the treatment of lower tract symptoms. Prospective study on 320 patients [Associazione di Serenoa repens , Urtica dioica e Pinus pinaster. Sicurezza ed efficacia nel trattamento dei sintomi del basso tratto ruinario. Studio prospettico su 320 pazienti]. Urologia2010;77(1):43-51. ">Pavone 2010</a>; <a href="./references#CD001423-bbs2-0062" title="PopaG , Hägele-KaddourH , WaltherC . Symptomatic efficacy of a sabal-urtica combination preparation in the therapy of benign prostatic syndrome: results of a placebo-controlled double-blind study [Symptomatische wirksamkeit eines sabal-urtica-kombinationspräparats in der therapie des benignen prostatasyndroms: ergebnisse einer plazebokontrollierten doppelblindstudie]. MMW Fortschritte der Medizin2005;147(Suppl 3):103-8. ">Popa 2005</a>; <a href="./references#CD001423-bbs2-0065" title="SinescuI , GeavleteP , MultescuR , GanguC , MicleaF , ComanI , et al. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urologia Internationalis2011;86:284-9. [DOI: 10.1159/000322645]">Sinescu 2011</a>; <a href="./references#CD001423-bbs2-0067" title="StepanovVN , SiniakovaLA , SarrazinB , RaynaudJP . Efficacy and tolerability of the lipidosterolic extract of Serenoarepens (Permixon®) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. Advances in Therapy1999;16(5):231-41. ">Stepanov 1999</a>; <a href="./references#CD001423-bbs2-0070" title="TaiebC , AugesM , CabanacF . BPH patients treated with phytotherapy: Results at 6 months. Urology2012;80(3):S220-S221. TaiebC , AugesM , PerrinP . Patients with BPH: Results at 6 months following treatment with phytotherapy versus other treatments. Value in Health2010;13(7):A480. TaiebC , CabanacF . Patients with BPH: Results at 6 months with phytotherapy vs other treatments. Urology2012;80(3):S220. ">Taieb 2010</a>; <a href="./references#CD001423-bbs2-0073" title="VinarovAZ , Aliaev IuG, ApolikhinOI , MazoEB , DarenkovSP , Demidko IuL, et al. Results of three-year clinical study of prostamol Uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression. Urologiia2010;6:3-10. [21433319]">Vinarov 2010</a>; <a href="./references#CD001423-bbs2-0076" title="ZlottaAR , TeillacP , RaynaudJP , SchulmanCC . Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon (R)), Tamsulosin or Finasteride. European Urology2005;48(2):269-276. ">Zlotta 2005</a>). </p> </li> <li> <p>Eight studies included the wrong study population (i.e. men with prostatitis or focus on changes in prostatic tissue) (<a href="./references#CD001423-bbs2-0031" title="AliaevIG , ApolikhinOI , MazoEB , VinarovAZ , LokshinKL , MedvedevAA , et al. Efficacy and safety of prostamol-Uno in patients with chronic abacterial prostatitis [ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ПРОСТАМОЛА-УНО У БОЛЬНЫХ ХРОНИЧЕСКИМ АБАКТЕРИАЛЬНЫМ ПРОСТАТИТОМ]. Urologiia2006;1:47-50. ">Aliaev 2009</a>; <a href="./references#CD001423-bbs2-0043" title="Di SiverioF , D'EramoG , LubranoC , FlammiaGP , SciarraA , PalmaE , et al. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. European Urology1992;21(4):309-14. [MEDLINE: 1993093014]">Di Silverio 1992</a>; <a href="./references#CD001423-bbs2-0056" title='MorgiaG , CiminoS , FavillaV , RussoGI , SquadritoF , MucciardiG , et al. Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study. International braz j urol: official journal of the Brazilian Society of Urology2013;39(2):214-221. '>Morgia 2013</a>; <a href="./references#CD001423-bbs2-0061" title="PecoraroS , AnnecchiaricoA , Gambardella M-C, SepeG . Efficacy of pretreatment with Serenoa repens on bleeding associated with transurethral resection of prostate [Effetto del pretrattamento con serenoa repens sul sanguinamento associato a resezione transuretrale della prostata]. Minerva Urologica e Nefrologica2004;56:73-8. ">Pecoraro 2004</a>; <a href="./references#CD001423-bbs2-0069" title="SuardiN , GandagliaG , NiniA , MontorsiF , PellucchiF , AgostiniA , et al. Effects of Difaprost R on voiding dysfunction, histology and inflammation markers in patients with benign prostatic hyperplasia who are candidates for surgical treatment. Minerva urologica e nefrologica [The Italian journal of urology and nephrology]2014;66(2):119-25. ">Suardi 2014</a>; <a href="./references#CD001423-bbs2-0071" title="Vela-NavarreteR , Escribano-BurgosM , Lopez FarreA , Garcia-CardosoJ , ManzarbeitiaF , CarrascoC . Serenoa repens treatment modifies BAX/BCL-2 index expression and CASPASE-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. The Journal of Urology2005;173:507-10. Vela-NavarreteR , Garcia CardosoJV , BaratA , ManzarbeitiaF , Lopez FarreA . BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. European Urology2003;44:549-55. ">Vela‐Navarrete 2005</a>; <a href="./references#CD001423-bbs2-0072" title="VeltriRW , MarksLS , MillerCM , BalesWD , FanJ , MacAiranML , et al. Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism. Urology2002;60:617-22. [PMID: 12385921]">Veltri 2002</a>; <a href="./references#CD001423-bbs2-0074" title="WeisserH , BehnkeB , HelpapB , BachD , KriegM . Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. European Urology1997;31(1):97-101. [MEDLINE: 1997184773]">Weisser 1997</a>). </p> </li> <li> <p>Twenty‐five studies compared <i>Serenoa repens</i> with active components or different doses (<a href="./references#CD001423-bbs2-0028" title="Adriazola SeminoM , Lozano OrtegaJL , Garcia CoboE , Tejeda BanezE , Romero RodriguezF . Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and Serenoa repens [Tratamiento sintomatico de la hipertrofia benigna de prostata. Estudio comparativo entre prazosin y Serenoa repens]. Archivos Espanoles de Urologia1992;45(3):211-3. [MEDLINE: 1993037631]">Adriazola Semino 1992</a>; <a href="./references#CD001423-bbs2-0030" title="AliL , HayatF , OpalS , KahnS , KahnQ , TariqK . Comparison of phytotherapy with alpha adrenocepters blockers in the treatment of symptomatic benign prostatic hyperplasia. Journal of Postgraduate Medical Institute2020;34(2):129-133. ">Ali 2020</a>; <a href="./references#CD001423-bbs2-0034" title="BartschG , DreikornK , SchontogerPS . Combined Sabal extract and Urtica extract versus finasteride in benign prostatic hyperplasia (stages I-II). UROLOGE A1998;37(1):83-84. ">Bartsch 1998</a>; <a href="./references#CD001423-bbs2-0035" title="BraeckmanJ , BruhwylerJ , VanderkerckhoveK , GéczyJ . Efficacy and safety of the extract of Serenoa repens in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytotherapy Research1997;1:558-63. BraeckmanJ , DenisL , deLevalJ , KeuppensF , CornetA , De Bruyne, et al. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. European Journal of Clinical Research1997;9:247-59. BraeckmanJ . The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Current Therapeutic Research1994;55(7):776-85. ">Braeckman 1997</a>; <a href="./references#CD001423-bbs2-0036" title="CaiT , MorgiaG , CarrieriG , TerroneC , ImbimboC , VerzeP , et al. An improvement in sexual function is related to better quality of life, regardless of urinary function improvement: results from the IDIProst Gold Study. Archivio italiano di urologia e andrologia2013;85(4):184‐189. ">Cai 2013</a>; <a href="./references#CD001423-bbs2-0037" title="CarraroJC , RaynaudJP , KochG , ChisholmGD , Di SilverioF , TeillacP , et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. The Prostate1996;29(4):231-40. [MEDLINE: 1997030765]CarraroJC , RaynaudJP , KochG , ChisholmGD , Di SilverioF , TeiucicP , et al. Extract of saw palmetto for treatment of symptomatic benign prostatic hyperplasia. Integrative Medicine1998;1(1):39-40. ">Carraro 1996</a>; <a href="./references#CD001423-bbs2-0038" title="ComarOB , Di RienzoA . Mepartricin versus Serenoa repens: double-blind study in 20 cases of benign prostate hypertrophy. Rivista Italiana di Biologia e Medicina1986;6(2):122-5. ">Comar 1986</a>; <a href="./references#CD001423-bbs2-0039" title="CTRI/2012/10/003049. A Clinical Study to Evaluate the Safety and Efficacy of Capsule Outflo in Patients with Benign Prostatic Hyperplasia. https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2012/10/003049 Date of registration: 08-10-2012. ">CTRI/2012/10/003049</a>; <a href="./references#CD001423-bbs2-0040" title="CTRI/2020/09/027521. A clinical study to assess the Efficacy and Safety of SAW-1720 in Benign Prostate Hyperplasia patients. https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2020/09/027521 Date of registration: 01-09-2020. ">CTRI/2020/09/027521</a>; <a href="./references#CD001423-bbs2-0041" title="DebruyneF , BoyleP , Calais Da SilvaF , GillenwaterJG , HamdyFC , PerrinP , et al. Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients—PERMAL study subset analysis [Evaluation du benefice clinique de Permixon® et de la tamsulosine dans le traitement de l'hypertrophie bénigne de la prostate (HBP) sévére: Analyse d'une sous-groupe de l'étude Permal]. European Urology2004;45:773-80. DebruyneF , BoyleP , Da SilvaFC , GillenwaterJG , HamdyFC , PerrinP , et al. Evaluation of the clinical benefit of permixon((R)) and tamsulosin in severe BPH patients—PERMAL study subset analysis. PROGRES EN UROLOGIE2004;14(3):326-331. DebruyneF , KochG , BoyleP , Da SilvaFC , GillenwaterJG , HamdyFC , et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study [Comparaison d'un produit de phytotherapie (Permixon) et d'un alpha-bloquant (tamsulosine) dans le traitement de l'hypertrophie benigne de la prostate: etude internationale randomisee d'une duree de 12 mois]. Progres en Urologie2002;12(3):384-94. DebruyneF , KochG , Da SilvaFC , GillenwaterJG , HamdyFC , PerrinP , et al. Comparison of a phytotherapeutic agent (Permixon®) with an a-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study [Comparaison d'un produit de phytothérapie (Permixon®) et d'un alpha-bloquant (tamsulosine) dans le traitement de l'hypertrophie bénigne de la prostate: étude internationale randomisée d'une durée de 12 mois]. Progrès en Urologie2002;41:497-507. ">Debruyne 2002</a>; <a href="./references#CD001423-bbs2-0044" title="Duborija-KovacevicN , SaboA , PajovicB . Pharmacoeconomic evaluation of three different medications for lower urinary tract symptoms associated with BPH: Herbal extract versus standard drugs. European Urology, Supplements2010;9(6):597-598. ">Duborija‐Kovacevic 2010</a>; <a href="./references#CD001423-bbs2-0045" title="EngelmannU , WaltherC , BondarenkoB , FunkP , SchläfkeS . Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. Arzneimittel-Forschung2006;56(3):222-9. ">Engelmann 2006</a>; <a href="./references#CD001423-bbs2-0046" title="EUCTR2011-005307-33-FR. Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicentric, randomised, double-blind, parallel-group prospect. https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-005307-33/results Start Date: 24-09-2012. ">EUCTR2011‐005307‐33‐FR</a>; <a href="./references#CD001423-bbs2-0050" title="GrassoM , MontesanoA , BuonaguidiA , CastelliM , LaniaC , RigattiP , et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Archivos Españoles de Urología1995;48(1):97-103. [MEDLINE: 1995251418]">Grasso 1995</a>; <a href="./references#CD001423-bbs2-0052" title="GuzmanR , IllnaitJ , MasR , FernandezL , PedrosoM , FernandezJ , et al. Efficacy and tolerability of Roystonea regia (D-004) and saw palmetto lipid extracts in men with symptomatic benign prostatic hyperplasia: a 24 weeks study. Gazzetta medica italiana archivio per LE scienze mediche2016;175(10):413‐420. RPCEC00000138. D-004 in patients with Bening Prostatic Hyperplasia. https://rpcec.sld.cu/en/trials/RPCEC00000138-En 04 January 2013. ">Guzman 2016</a>; <a href="./references#CD001423-bbs2-0053" title="HamdvFC , ChopinDK , AuthieD , DeschaseauxP , PérierA , Raynaud J-P. Prostatic volume does not correlate with efficacy of treatment for mild to moderate benign prostatic hyperplasia using either finasteride or phytotherapy (permixon®). British Journal of Urology1997;80(SUPPL. 2):195. RaynaudJP , AuthiéD , DeschaseauxP , PérierA , FietJ , PerrinP . Influence of age and endocrine treatments (permixon ® and finasteride) on sexual function in benign prostatic hyperplasia (BPH) patients. British Journal of Urology1997;80(Suppl 2):206. ">Hamdv 1997</a>; <a href="./references#CD001423-bbs2-0055" title="LatilA , PétrissansMT , RouquetJ , RobertG , dela TailleA . Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate2015;75(16):1857‐1867. ">Latil 2015</a>; <a href="./references#CD001423-bbs2-0057" title="ISRCTN73316039. Sprite study. https://www.isrctn.com/ISRCTN73316039 Registration date: 22/05/2015. MorgiaG , VespasianiG , PareoRM , VoceS , MadoniaM , CariniM , et al. Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study). BJU International2018;122(2):317‐325. ">Morgia 2018</a>; <a href="./references#CD001423-bbs2-0058" title="NCT00797394. Efficacy of natural extract 2007RD01 combined with Saw Palmetto in benign prostatic hyperplasia patients compared to Saw Palmetto. https://clinicaltrials.gov/ct2/show/NCT00797394 First Posted: November 25, 2008. [NCT00797394]">NCT00797394</a>; <a href="./references#CD001423-bbs2-0059" title="PannunzioE , DascenzoR , GiardinettiF , CiviliP , PersichelliE . Serenoa repens in the treatment of human benign prostatic hyperplasia (BPH). Journal of Urology1987;137(4):A226-A226. PannunzioE , D’AscenzoR , GiardinettiF , CiviliP , PersichelliE . Serenoa repens vs. Gestorone caproate in the treatment of benign prostatic hypertension: a randomized study [Serenoa repens vs. gestonorone caproato nel trattamento dell’ipertofia prostatica benigna: Studio randomizzato]. Urologia1986;53(5):696-705. ">Pannunzio 1986</a>; <a href="./references#CD001423-bbs2-0063" title="RomaniukM , GorpynchenkoI , GurzhenkoJ , KlimenkoP , ShulyakA , SpiridonenkoV . PROSPECT study (PROStamol: perspectives of combined therapy) in patients with BPH. European urology, supplements2013;12(4):e1150. ">Romaniuk 2013</a>; <a href="./references#CD001423-bbs2-0064" title="RovedaS , ColomboP . Clinical controlled trial on therapeutical bioequivalence and tolerability of Serenoa repens oral capsules 160 mg or rectal capsules 640 mg [Sperimentazione clinica controllata sulla bioequivalenza terapeutica e sulla tollerabilita dei prodotti a base di Serenoa repens in capsule da 160 mg o capsule rettali da 640 mg]. Archivio di Medicina Interna1994;46(2):61-75. ">Roveda 1994</a>; <a href="./references#CD001423-bbs2-0066" title="SökelandJ , AlbrechtJ . Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome [Kombination aus Sabal- und Urticaestrakt vs. finasterid bei BPH (Stad. I bis II nach Alken); Vergleich der therapeutischen wirksamkeit in einer einjahrigen doppelblindstudie]. Urologe A1997;36(4):327-33. [MEDLINE: 1997419443]SökelandJ , WaltherC . A combination preparation of sabal and urtica extract versus finasteride in benign prostatic hyperplasia (BPH)—an analysis of data regarding prostatic volume and treatment success. Zeitschrift fur Phytotherapie2000;21(6):299-305. SökelandJ . Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. British Journal of Urology International2000;86:439-42. ">Sökeland 1997</a>; <a href="./references#CD001423-bbs2-0068" title="StrauchG , PerlesP , VergultG , GabrielM , GibelinB , CummingsS , et al. Comparison of finasteride (Proscar®) and Serenoa repens (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers. European Urology1994;26(3):247-52. [MEDLINE: 1995104266]">Strauch 1994</a>; <a href="./references#CD001423-bbs2-0075" title="YamanishiT , YasudaK , KamaiT , TsujiiT , SakakibaraR , UchiyamaT , et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. International journal of urology2004;11(7):501‐509. ">Yamanishi 2004</a>). </p> </li> </ul> </p> <section id="CD001423-sec-0057"> <h5 class="title">Studies awaiting classification</h5> <p>See <a href="./references#CD001423-sec-0142" title="">Characteristics of studies awaiting classification</a>. </p> <p>We identified 24 studies (7 from the previous version of the review) with no available full text (<a href="./references#CD001423-bbs2-0077" title="AliaevIG , VinarovAZ , LokshinKL , SpivakLG . Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy. Urologiia (Moscow, Russia : 1999)2007;(2):80-82. ">Aliaev 2007</a>; <a href="./references#CD001423-bbs2-0078" title="Anonymous. Benign prostatic syndrome. Urinary urgency and micturition frequency reduced with plant preparation [Benignes Prostatasyndrom. Harndrang und Miktionsfrequenz mit Pflanzenpraparat reduzieren]. MMW Fortschritte der Medizin2005;147(40):52-3. ">Anonymous 2005</a>; <a href="./references#CD001423-bbs2-0079" title="BercovichE , SaccomanniM . Analysis of the results obtained with a new phytotherapeutic association for LUTS versus control. Urologia2010;77(3):180‐186. ">Bercovich 2010</a>; <a href="./references#CD001423-bbs2-0080" title='BuckAC , MahendraV , BayneCW , RossM , HabibFK . An investigation into the "in vivo" effect of Permixon, an extract of the American dwarf palm, Serenoa repens, on human benign prostatic hyperplasia. Journal of Urology2002;167(4):374-374. '>Buck 2002</a>; <a href="./references#CD001423-bbs2-0081" title="CarrerasJO . Our experience with hexanic extract of Serenoa repens in the treatment of benign prostatic hypertrophy. Archivos Espanoles de Urologia1987;40(5):310-313. ">Carreras 1987</a>; <a href="./references#CD001423-bbs2-0082" title="CukierJ , DucassouJ , Le GuillouM , LericheA , LobelB , ToubolJ . Permixon versus placebo; results of a multicenter study [Permixon versus placebo; resultats d'une étude multicentrique]. Comptes Rendus de Therapeutique et de Pharmacologie Clinique1985;4:15-21. ">Cukier 1985</a>; <a href="./references#CD001423-bbs2-0083" title="DatheG , SchmidH . Phytotherapy of benign prostate hyperplasia with Serenoa repens extract (permixon®). Urologe - Ausgabe B1991;31(5):220-223. ">Dathe 1991</a>; <a href="./references#CD001423-bbs2-0084" title="DiehlKF , KromerF , HorakT , NahlerG . Treatment of benign prostate hyperplasia with a combination preparation from sabal and urtica extract in urological practice. Journal fur Urologie und Urogynakologie2005;12(2):21-24. ">Diehl 2005</a>; <a href="./references#CD001423-bbs2-0085" title="EmiliE , Lo CignoM , PetroneU . Clinical results on a new drug in the therapy of prostate hypertrophy (Permixon) [Risultati clinici su un nuovo farmaco nella terapia dell'ipertofia della prostata (Permixon)]. Urologia1983;50:1042-8. ">Emili 1983</a>; <a href="./references#CD001423-bbs2-0086" title="FabriciusPG , Vahlensieck W Jr. Sabal extract in a single daily dose in the treatment of benign prostate hyperplasia. Therapiewoche1993;43(30-31):1616-1620. ">Fabricius 1993</a>; <a href="./references#CD001423-bbs2-0087" title="GabricV , MiskicH . Treatment of benign prostate adenoma and chronic prostatitis [Behandlung des benignen prostata-adenoms und der chronischen prostatatitis]. Therapiewoche1987;37:1775-88. ">Gabric 1987</a>; <a href="./references#CD001423-bbs2-0088" title="GreenKA , CampbellPS . Saw palmetto: An effective form of phytotherapy for the treatment of benign prostate hyperplasia (BPH)?Biology of Reproduction2000;62:187-187. ">Green 2000</a>; <a href="./references#CD001423-bbs2-0089" title="LöbelenzJ . Extractum Sabal fructus in benign prostatic hyperplasia (BPH). Stage I and II clinical trial [Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). Klinische prufung im stadium I und II]. Therapeutikon1992;6(1-2):34-7. ">Löbelenz 1992</a>; <a href="./references#CD001423-bbs2-0090" title="Martínez AgullóE , Gallego GómezJ , Jiménez CruzFJ . Medical treatment of the prostatism syndrome. Comparative study. Archivos espanoles de urologia1987;40(4):247‐253. ">Martínez 1987</a>; <a href="./references#CD001423-bbs2-0091" title="MatteiFM , CaponeM , AcconciaA . Drug therapy of benign prostatic hyperplasia with saw palmetto extract [Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme]. TW Urologie Nephrologie1990;2:346-50. MatteiFM , CaponeM , AcconciaA . Liposterolic extract of Serenoa Repens in management of benign prostatic hypertrophy. Urologia1988;55(5):547-552. ">Mattei 1990</a>; <a href="./references#CD001423-bbs2-0092" title="MohantyNK , JhaRJ , DuttC . Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic Grade I to Grade II benign prostatic hyperplasia (PBH). Indian Journal of Urology1999;16(1):26-31. MohantyNK . Serenoa repens versus placebo in management of benign prostatic hyperplasia (bph)—a randomised double blind control clinical trial. Nephrology, urology, transplantation society of SAARC, Sri Lanka1999:137. ">Mohanty 1999</a>; <a href="./references#CD001423-bbs2-0093" title="NeumannHG . Combination treatment of benign prostate hyperplasia with phytotherapy and selective alpha 1 blocking agents. Urologe - Ausgabe B1993;33(6):384-385. ">Neumann 1993</a>; <a href="./references#CD001423-bbs2-0094" title="RazumovSV , DereviankoII , SivkovAV . Prostamol-uno in the treatment of benign prostatic hyperplasia. Urologiia (Moscow, Russia : 1999)2001;(2):35-37. ">Razumov 2001</a>; <a href="./references#CD001423-bbs2-0095" title="JPRN-UMIN000035036. A verification study on improvement of urination issues with ingestion of saw palmetto fruit extract: a randomized double-blind, parallel-group, placebo-controlled study. https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039948 Date of registration: 27/11/2019. SekikawaT , et al. Verification Study on the Effects of Saw Palmetto Fruit Extract on Urination Issues―A Randomized Double-blind, Parallel-group, Placebo-controlled Study. Yakuritochiryō [Pharmacology and Therapy]2020;48:429-440. ">Sekikawa 2020</a>; <a href="./references#CD001423-bbs2-0096" title="TascaA , BarulliM , CavazzanaA , ZattoniF , ArtibaniW , PaganoF . Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs placebo [Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo]. Minerva Urologica e Nefrologica1985;37:87-91. [PMID: 2413558]TascaA , BarulliM , CavazzanaA , ZattoniF , ArtibaniW , PaganoF . Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo [Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo]. Minerva Urologica e Nefrologica1985;37:87-91. [MEDLINE: 1986019370]">Tasca 1985</a>; <a href="./references#CD001423-bbs2-0097" title="TkachukVN , Al'-ShukriSK , AleksandrovVP , Kniaz'kinIV . Treatment of benign prostatic hypertrophy with prostaplant. Urologiia (Moscow, Russia : 1999)2002;(3):16-18. ">Tkachuk 2002</a>; <a href="./references#CD001423-bbs2-0098" title="Vahlensieck W Jr, FabriciusPG , MuschterR , UysalA . Therapy of benign prostate hyperplasia with sabal fruit extract SG 291 is effective and causes few side-effects. Therapiewoche1995;45(29):1728-1736. Vahlensieck W Jr, VolpA , KuntzeM , LubosW . Change of miction in patients with benign prostate hyperplasia during treatment with sabal extract. Urologe - Ausgabe B1993;33(6):380-383. ">Vahlensieck 1993</a>; <a href="./references#CD001423-bbs2-0099" title="VinarovAZ , AliaevIG , LokshinKL . Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma. Urologiia (Moscow, Russia : 1999)2009;(1):84, 86-87. ">Vinarov 2009</a>; <a href="./references#CD001423-bbs2-0100" title="WehrA . Therapy of benign prostate hyperplasia with sabal extract IDS 89: Long-term study proofs the efficiency. Therapiewoche1995;45(5):313-314. ">Wehr 1995</a>). </p> </section> <section id="CD001423-sec-0058"> <h5 class="title">Ongoing studies</h5> <p>We also identified five ongoing studies (<a href="./references#CD001423-bbs2-0101" title="ISRCTN84633360. Permixon (R) 320 mg once a day open label treatment for patients participating in the placebo controlled study. https://www.isrctn.com/ISRCTN42774128 Registration date: 22/04/2009. ">ISRCTN84633360</a>; <a href="./references#CD001423-bbs2-0102" title="JPRN-UMIN000023274. A double-blind, randomized, placebo-controlled clinical trial to investigate the effect of the foods containing plant extract (No.SB2805). https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026820 22 July 2016. ">JPRN‐UMIN000023274</a>; <a href="./references#CD001423-bbs2-0103" title="JPRN-UMIN000027902. A verification study on improvement of problems with urination due to ingestion of the food containing saw palm extracts: a randomized double-blind, parallel-group, placebo-controlled study. https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031969 23 June 2017. ">JPRN‐UMIN000027902</a>; <a href="./references#CD001423-bbs2-0104" title="NCT00497939. The Effectiveness of Saw Palmetto and Sanmiaoshan on Benign Prostatic Hyperplasia in Chinese Patients. https://clinicaltrials.gov/show/NCT00497939 First Posted: July 9, 2007. ">NCT00497939</a>; <a href="./references#CD001423-bbs2-0105" title="NCT02121613. PERmixon® in LUTS Evaluation Study (PERLES). https://ClinicalTrials.gov/show/NCT02121613 First Posted: April 23, 2014. [GERMAN CLINICAL TRIALS REGISTER: DRKS00008796]">NCT02121613</a>). See <a href="./references#CD001423-sec-0143" title="">Characteristics of ongoing studies</a>. </p> </section> </section> </section> <section id="CD001423-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessments for each result in <a href="./full#CD001423-tbl-0001">summary of findings Table 1</a> and <a href="./full#CD001423-tbl-0002">summary of findings Table 2</a>, including all domain judgments and support for judgment, is located in the risk of bias section, at the side of all forest plots. The signaling questions' responses can be found on the Open Science Framework storage (<a href="https://osf.io/65m8e" target="_blank">osf.io/65m8e</a>). </p> <p>The risk of bias of outcomes across all results and domains was mostly 'some concerns' due to a lack of prespecification of outcomes and analysis plans. We assessed three studies as at overall low risk of bias (<a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a>; <a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a>; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>). We assessed three studies as at high risk of bias due to missing outcome data or bias in the measurement of the outcome (due to lack of blinding), in addition to some concerns regarding selective reporting (<a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>). </p> </section> <section id="CD001423-sec-0060"> <h3 class="title" id="CD001423-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD001423-tbl-0001"><b>Summary of findings 1</b><i>Serenoa repens</i> compared to placebo or no intervention</a>; <a href="./full#CD001423-tbl-0002"><b>Summary of findings 2</b><i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention</a> </p> <section id="CD001423-sec-0061"> <h4 class="title">1. <i>Serenoa repens</i> versus placebo or no intervention (short term) </h4> <p>Results for this comparison are based on predefined sensitivity analyses limited to studies at low risk of bias. See <a href="./full#CD001423-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD001423-sec-0062"> <h5 class="title">1.1. Urologic symptoms</h5> <p><i>Serenoa repens</i> results in little to no difference in urologic symptoms at short‐term follow‐up (3 to 6 months; mean difference (MD) −0.90, 95% confidence interval (CI) −1.74 to −0.07; I<sup>2</sup> = 68%; 9 studies, 1681 participants; high‐certainty evidence). All heterogeneity was explained by a single study of 304 participants that compared <i>Serenoa repens</i> to placebo and showed a difference in IPSS scores of −2.77 (95% CI −3.71 to −1.83) (<a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a>), which is statistically significant but clinically unimportant. We did not downgrade the certainty of the evidence for inconsistency, considering a minimally contextualized approach and our predefined MCID. We also did not downgrade for risk of bias, since our main analysis was based on a sensitivity analysis excluding studies at high risk of bias (<a href="./references#CD001423-fig-0002" title="">Analysis 1.1</a>). However, this analysis did not materially differ from the analysis including all studies (<a href="./references#CD001423-fig-0003" title="">Analysis 1.2</a>). </p> <p>One study with 101 participants found a reduction of urologic symptoms with <i>Serenoa repens</i> (P &lt; 0.01) (<a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>). Another study with 1011 participants found a decrease in urologic symptoms with <i>Serenoa repens</i> compared to placebo at 12 months follow‐up (P = 0.04) (<a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>). </p> </section> <section id="CD001423-sec-0063"> <h5 class="title">1.2. Quality of life</h5> <p><i>Serenoa repens</i> results in little to no difference in quality of life at short‐term follow‐up (3 to 6 months, MD −0.20, 95% CI −0.40 to −0.00; I<sup>2</sup> = 39%; 5 studies, 1001 participants; high‐certainty evidence). We did not downgrade the certainty of the evidence for risk of bias since, our main analysis was based on a sensitivity analysis excluding studies at high risk of bias (<a href="./references#CD001423-fig-0004" title="">Analysis 1.3</a>). However, this analysis did not materially differ from the analysis including all studies (<a href="./references#CD001423-fig-0005" title="">Analysis 1.4</a>). </p> </section> <section id="CD001423-sec-0064"> <h5 class="title">1.3. Adverse events</h5> <p><i>Serenoa repens</i> probably results in little to no difference in adverse events (1 to 17 months, risk ratio (RR) 1.01, 95% CI 0.77 to 1.31; I<sup>2</sup> = 18%; 12 studies, 2399 participants; moderate‐certainty evidence). Based on 164 cases per 1000 men in the placebo group, this corresponds to 2 more (38 fewer to 51 more) per 1000 men in the <i>Serenoa repens</i> group. We did not downgrade the certainty of the evidence for risk of bias, since our main analysis was based on a sensitivity analysis excluding studies at high risk of bias (<a href="./references#CD001423-fig-0006" title="">Analysis 1.5</a>). However, this analysis did not materially differ from the analysis including all studies (<a href="./references#CD001423-fig-0007" title="">Analysis 1.6</a>). Nonetheless, we downgraded one level due to imprecision. </p> <p>We did not incorporate three studies into the meta‐analysis because they reported no adverse events in either the treatment or control group (<a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>; <a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a>; <a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>). </p> <p>The most commonly reported adverse events were headache, gastrointestinal disorders (e.g. diarrhea, nausea and vomiting, stomach upset), upper respiratory symptoms (e.g. rhinitis), ejaculation disorders, musculoskeletal symptoms (e.g. arthralgia in the knees and muscular arm pain), and dizziness. Many of these symptoms may be attributable to co‐interventions (alpha‐blockers). </p> <p>Few studies in each category precluded subgroup analyses according to age, symptom severity, prostate size, and type of extract (see <a href="#CD001423-sec-0050">Included studies</a>). </p> </section> <section id="CD001423-sec-0065"> <h5 class="title">1.4. Subgroup analysis</h5> <section id="CD001423-sec-0066"> <h6 class="title">1.4.1. Type of <i>Serenoa repens</i> preparation </h6> <p>We were unable to detect differences in urologic symptoms when comparing the effects of hexanic versus non‐hexanic extract (P = 0.23, see <a href="./references#CD001423-fig-0008" title="">Analysis 1.7</a>). </p> </section> <section id="CD001423-sec-0067"> <h6 class="title">1.4.2. Other subgroup analyses</h6> <p>Few studies in each category precluded subgroups based on participant age and severity of lower urinary tract symptoms (see <a href="#CD001423-sec-0050">Included studies</a>). </p> </section> </section> <section id="CD001423-sec-0068"> <h5 class="title">1.5. Sensitivity analysis</h5> <p>We conducted a sensitivity analysis excluding studies at overall high risk of bias. Given that these analyses provided moderate‐ to high‐certainty evidence, we incorporated them into the main results and summary of findings table (see above outcomes 1.1, 1.2, and 1.3 and <a href="./references#CD001423-fig-0002" title="">Analysis 1.1</a>; <a href="./references#CD001423-fig-0004" title="">Analysis 1.3</a>; <a href="./references#CD001423-fig-0006" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD001423-sec-0069"> <h4 class="title">2. <i>Serenoa repens</i> versus placebo or no intervention (long term) </h4> <section id="CD001423-sec-0070"> <h5 class="title">2.1. Urologic symptoms</h5> <p><i>Serenoa repens</i> results in little to no difference in urologic symptoms at long‐term follow‐up (12 to 17 months, MD 0.07, 95% CI −0.75 to 0.88; I<sup>2</sup> = 34%; 3 studies, 898 participants; high‐certainty evidence). We did not downgrade the certainty of the evidence for risk of bias, since our main analysis was based on a sensitivity analysis excluding studies at high risk of bias (<a href="./references#CD001423-fig-0009" title="">Analysis 1.8</a>). However, this analysis did not materially differ from the analysis including all studies (<a href="./references#CD001423-fig-0010" title="">Analysis 1.9</a>). </p> </section> <section id="CD001423-sec-0071"> <h5 class="title">2.2. Quality of life</h5> <p><i>Serenoa repens</i> results in little to no difference in quality of life at long‐term follow‐up (12 to 17 months, MD −0.11, 95% CI −0.41 to 0.19; I<sup>2</sup> = 65%; 3 studies, 882 participants; high‐certainty evidence). We did not downgrade the certainty of the evidence for risk of bias, since our main analysis was based on a sensitivity analysis excluding studies at high risk of bias (<a href="./references#CD001423-fig-0011" title="">Analysis 1.10</a>). However, this analysis did not materially differ from the analysis including all studies (<a href="./references#CD001423-fig-0012" title="">Analysis 1.11</a>).  </p> </section> <section id="CD001423-sec-0072"> <h5 class="title">2.3. Adverse events</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD001423-sec-0073"> <h5 class="title">2.4. Subgroup analysis</h5> <p>Few studies in each category precluded these subgroup analyses (see <a href="#CD001423-sec-0050">Included studies</a>). </p> </section> <section id="CD001423-sec-0074"> <h5 class="title">2.5. Sensitivity analysis</h5> <p>We conducted a sensitivity analysis excluding studies at overall high risk of bias. Given that these analyses provided high‐certainty evidence, we incorporated them into the main results and summary of findings table (see above outcomes 2.1 and 2.2 and <a href="./references#CD001423-fig-0009" title="">Analysis 1.8</a>; <a href="./references#CD001423-fig-0011" title="">Analysis 1.10</a>). </p> </section> </section> <section id="CD001423-sec-0075"> <h4 class="title">3. <i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention </h4> <p>See <a href="./full#CD001423-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD001423-sec-0076"> <h5 class="title">3.1. Urologic symptoms</h5> <p>Different phytotherapeutic agents that include <i>Serenoa repens</i> may result in little to no difference in urologic symptoms compared to placebo at short‐term follow‐up (12 to 24 weeks, MD −2.41, 95% CI −4.54 to −0.29; I<sup>2</sup> = 67%; 4 studies, 460 participants; low‐certainty evidence; <a href="./references#CD001423-fig-0013" title="">Analysis 2.1</a>). The certainty of the evidence is low due to imprecision and inconsistency. </p> <section id="CD001423-sec-0077"> <h6 class="title">3.1.1. Studies not included in meta‐analysis</h6> <p>One study with 60 participants found a 36% reduction in the total IPSS median score in the active group (<i>Serenoa repens</i> , lycopene, <i>Prunus africana</i> , <i>Epilobium parviflorum</i> , and <i>Cucurbita pepo</i>) compared to 8% in the placebo group at three months follow‐up (P &lt; 0.05) (<a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>). Another study with 225 participants found a greater decrease in IPSS scores for combination therapy (<i>Serenoa repens</i>, lycopene, and selenium) compared to control at 12‐month follow‐up (median change 2.0, range −3 to −1, P &lt; 0.01) (<a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>). One study reported as an abstract did not provide comparative data (only a decrease in IPSS in the intervention group) (<a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a>). </p> </section> </section> <section id="CD001423-sec-0078"> <h5 class="title">3.2. Quality of life</h5> <p>We are very uncertain about the effects of these agents on quality of life (very low‐certainty evidence). In one study with 40 participants, 84.2% of participants in the intervention group had improvements in their quality of life after six months of treatment compared to 11.1% of participants in the placebo group (P &lt; 0.001) (<a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a>). Another study with 225 participants found little to no difference in quality of life scores (median change 0, range −0.1 to 1) (<a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>). The certainty of the evidence is very low due to risk of bias, inconsistency, and imprecision. </p> </section> <section id="CD001423-sec-0079"> <h5 class="title">3.3. Adverse events</h5> <p>Different phytotherapeutic agents that include <i>Serenoa repens</i> may result in little to no difference in occurrence of adverse events; however, the CIs included substantial benefits and harms (12 to 48 weeks, RR 0.91, 95% CI 0.58 to 1.41; I<sup>2</sup> = 0%; 4 studies, 481 participants; low‐certainty evidence; <a href="./references#CD001423-fig-0014" title="">Analysis 2.2</a>). Based on 132 cases per 1000 men in the placebo group, this corresponds to 12 fewer (55 fewer to 54 more) per 1000 men in the combined phytotherapeutic agents with <i>Serenoa repens</i> group. We did not incorporate two studies into the meta‐analysis because they reported no adverse events in either the treatment or control group (<a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a>; <a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>). The certainty of the evidence is low due to severe imprecision. </p> <p>Another study with 225 participants reported no significant differences in treatment‐related adverse events (P = 0.67) (<a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>). </p> <p>The most commonly reported adverse events were headache, gastrointestinal disorders (e.g. diarrhea, nausea and vomiting, dyspepsia), upper respiratory symptoms (e.g. rhinitis), ejaculation disorders, musculoskeletal symptoms (e.g. arthralgia in the knees and pain), and dizziness. Many of these symptoms may be attributable to co‐interventions (alpha‐blockers). </p> </section> <section id="CD001423-sec-0080"> <h5 class="title">3.4. Subgroup analysis</h5> <p>Few studies in each category precluded these subgroup analyses (see <a href="#CD001423-sec-0050">Included studies</a>). </p> </section> <section id="CD001423-sec-0081"> <h5 class="title">3.5. Sensitivity analysis</h5> <p>We were unable to conduct a sensitivity analysis because the meta‐analyses did not include studies at overall high risk of bias. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001423-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001423-sec-0082"></div> <section id="CD001423-sec-0083"> <h3 class="title" id="CD001423-sec-0083">Summary of main results</h3> <p>For this update, we narrowed the review question and included 27 studies (of which 9 were new studies) with 4656 participants, 19 studies comparing <i>Serenoa repens</i> with placebo and 8 studies comparing <i>Serenoa repens</i> in combination with other phytotherapeutic agents versus placebo. </p> <p><b><i>Serenoa repens</i> versus placebo or no intervention</b> </p> <p>Based on predefined sensitivity analyses limited to studies at low risk of bias, <i>Serenoa repens</i> results in little to no difference in urologic symptoms and quality of life at short‐term follow‐up. <i>Serenoa repens</i> probably results in little to no difference in adverse events. </p> <p><i>Serenoa repens</i> results in little to no difference in urologic symptoms and quality of life at long‐term follow‐up. There were no data on long‐term adverse events for this comparison. </p> <p><b><i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention</b> </p> <p>Phytotherapeutic agents with various agents, including <i>Serenoa repens</i>, may result in little to no difference in urologic symptoms compared to placebo at short‐term follow‐up. We are very uncertain about the effects of these agents on quality of life. These agents may result in little to no difference in the occurrence of adverse events; however, the confidence intervals included substantial benefits and harms. </p> </section> <section id="CD001423-sec-0084"> <h3 class="title" id="CD001423-sec-0084">Overall completeness and applicability of evidence</h3> <p>While there has been a growing body of research since the last update of this review, our conclusions remain unchanged. Clinical practice guidelines have since deprioritized <i>Serenoa repens</i> in their treatment pathways. </p> <p> <ul id="CD001423-list-0019"> <li> <p>The 2021 Guideline of the American Urological Association focuses on the treatment of LUTS attributed to BPH using common surgical techniques and minimally invasive surgical therapies, thus the information on the different types of medical interventions is not deepened, much less the use of <i>Serenoa repens</i> (<a href="./references#CD001423-bbs2-0143" title="LernerLB , McVaryKT , BarryMJ , BixlerBR , DahmP , DasAK , et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management. Journal of Urology2021;206(4):806-817. [DOI: 10.1097/JU.0000000000002183]">Lerner 2021</a>). </p> </li> <li> <p>A previous version of this guideline from 2010 mentioned that the available data do not suggest that <i>Serenoa repens</i> has a clinically significant effect on LUTS secondary to BPH (<a href="./references#CD001423-bbs2-0148" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793-1803.">McVary 2011</a>). Furthermore, it adds that no dietary supplement, combined herbal medicine, or other unconventional therapy is recommended to manage LUTS secondary to BPH due to the paucity of high‐quality published trials (<a href="./references#CD001423-bbs2-0148" title="McVaryKT , RoehrbornCG , AvinsAL , BarryMJ , BruskewitzRC , DonnellRF , et al. Update on AUA guideline on the management of benign prostatic hyperplasia. Journal of Urology2011;185(5):1793-1803.">McVary 2011</a>). </p> </li> <li> <p>The European Association of Urology guidelines on the management of non‐neurogenic male LUTS recommends several therapeutic and surgical interventions in men with BPH (<a href="./references#CD001423-bbs2-0123" title="European Association of Urology. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Amsterdam: European Association of Urology, 2022.">EAU 2022</a>). This guideline recommends offering the hexane extract of <i>Serenoa repens</i> to men with LUTS who want to avoid possible adverse events, especially those related to sexual function (weak recommendation), informing the patient that the magnitude of efficacy may be modest (strong recommendation) (<a href="./references#CD001423-bbs2-0123" title="European Association of Urology. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Amsterdam: European Association of Urology, 2022.">EAU 2022</a>). Our review offers a further cautionary note about the use of <i>Serenoa repens.</i> </p> </li> <li> <p>The Korean Urological Association guidelines for the evidence‐based diagnosis and treatment of BPH provide basic information on diagnostic testing, drug therapy, and surgical treatment, but do not mention <i>Serenoa repens</i> as a management option (<a href="./references#CD001423-bbs2-0169" title="YeoJK , ChoiH , BaeJH , KimJH , YangSO , OhCY , et al. Korean clinical practice guideline for benign prostatic hyperplasia. Investigative and clinical urology2016;57(1):30-44. [DOI: 10.4111/icu.2016.57.1.30]">Yeo 2016</a>). </p> </li> </ul> </p> <p>Considering cut‐off points of 40 mL and 80 mL for small, medium, and large prostates, all studies included men with small‐ to average‐size prostates and moderate urologic symptoms. We found no studies in men with large prostates, and only a few studies of men with more severe urologic symptoms (see <a href="#CD001423-tbl-0003">Table 1</a>). This evidence is therefore only be applicable to this population (<a href="./references#CD001423-bbs2-0127" title="FrancoJVA , TesolinP , JungJH . Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures. Prostate International2023;11(1):1-7. [DOI: 10.1016/j.prnil.2023.01.002]">Franco 2023</a>). </p> <p>Few studies included co‐interventions such as tamsulosin (<a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a>; <a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a>; <a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>; <a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a>). However, this did not contribute to statistical heterogeneity when analyzing the outcomes of adverse events. Nonetheless, many of those adverse events described narratively (see footnotes in <a href="./references#CD001423-fig-0006" title="">Analysis 1.5</a> and <a href="./references#CD001423-fig-0014" title="">Analysis 2.2</a>) include dizziness and ejaculatory disorders, which are typically associated with alpha‐blockers (<a href="./references#CD001423-bbs2-0144" title="MansbartF , KienbergerG , SönnichsenA , MannE . Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatrics2022;22(1):771. [DOI: 10.1186/s12877-022-03415-7]">Mansbart 2022</a>). </p> </section> <section id="CD001423-sec-0085"> <h3 class="title" id="CD001423-sec-0085">Quality of the evidence</h3> <p>The overall certainty of the evidence was high for the main comparison, except for adverse events, for which we identified imprecision. We followed a similar approach to previous versions of this review, excluding studies at high risk of bias from our primary analysis. For the second comparison, however, we had additional concerns about precision and inconsistency across outcomes. </p> <p>Not all studies provided full details of critical outcomes such as urologic symptoms, quality of life, and adverse events, which would be desirable considering men’s values and preferences (<a href="./references#CD001423-bbs2-0116" title="DahmP , MacDonaldR , McKenzieL , JungJH , GreerNL , WiltT . Newer minimal-invasive treatment modalities to treat lower urinary tract symptoms attributed to benign prostatic hyperplasia. European Urology Open Science2021;26:72-82.">Dahm 2021</a>). </p> </section> <section id="CD001423-sec-0086"> <h3 class="title" id="CD001423-sec-0086">Potential biases in the review process</h3> <p>We could not locate the full text of seven of the original studies in the review, which could not be re‐analyzed using the updated methods (<a href="./references#CD001423-bbs2-0082" title="CukierJ , DucassouJ , Le GuillouM , LericheA , LobelB , ToubolJ . Permixon versus placebo; results of a multicenter study [Permixon versus placebo; resultats d'une étude multicentrique]. Comptes Rendus de Therapeutique et de Pharmacologie Clinique1985;4:15-21. ">Cukier 1985</a>; <a href="./references#CD001423-bbs2-0085" title="EmiliE , Lo CignoM , PetroneU . Clinical results on a new drug in the therapy of prostate hypertrophy (Permixon) [Risultati clinici su un nuovo farmaco nella terapia dell'ipertofia della prostata (Permixon)]. Urologia1983;50:1042-8. ">Emili 1983</a>; <a href="./references#CD001423-bbs2-0087" title="GabricV , MiskicH . Treatment of benign prostate adenoma and chronic prostatitis [Behandlung des benignen prostata-adenoms und der chronischen prostatatitis]. Therapiewoche1987;37:1775-88. ">Gabric 1987</a>; <a href="./references#CD001423-bbs2-0089" title="LöbelenzJ . Extractum Sabal fructus in benign prostatic hyperplasia (BPH). Stage I and II clinical trial [Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). Klinische prufung im stadium I und II]. Therapeutikon1992;6(1-2):34-7. ">Löbelenz 1992</a>; <a href="./references#CD001423-bbs2-0091" title="MatteiFM , CaponeM , AcconciaA . Drug therapy of benign prostatic hyperplasia with saw palmetto extract [Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme]. TW Urologie Nephrologie1990;2:346-50. MatteiFM , CaponeM , AcconciaA . Liposterolic extract of Serenoa Repens in management of benign prostatic hypertrophy. Urologia1988;55(5):547-552. ">Mattei 1990</a>; <a href="./references#CD001423-bbs2-0092" title="MohantyNK , JhaRJ , DuttC . Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic Grade I to Grade II benign prostatic hyperplasia (PBH). Indian Journal of Urology1999;16(1):26-31. MohantyNK . Serenoa repens versus placebo in management of benign prostatic hyperplasia (bph)—a randomised double blind control clinical trial. Nephrology, urology, transplantation society of SAARC, Sri Lanka1999:137. ">Mohanty 1999</a>; <a href="./references#CD001423-bbs2-0096" title="TascaA , BarulliM , CavazzanaA , ZattoniF , ArtibaniW , PaganoF . Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs placebo [Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo]. Minerva Urologica e Nefrologica1985;37:87-91. [PMID: 2413558]TascaA , BarulliM , CavazzanaA , ZattoniF , ArtibaniW , PaganoF . Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of Serenoa repens. Double-blind clinical study vs. placebo [Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo]. Minerva Urologica e Nefrologica1985;37:87-91. [MEDLINE: 1986019370]">Tasca 1985</a>). We contacted the original authors of the review and updates, and they did not hold copies of those studies. In addition to our existing library resources, we also posted a task in Cochrane TaskExchange (currently known as Cochrane Engage) to ask for help on this issue, without success. Based on the characteristics described in the previous version of the review (and available in the <a href="./references#CD001423-sec-0142" title="">Characteristics of studies awaiting classification</a> section), these studies primarily focused on non‐validated outcome measures and Q<sub>max</sub>, which would not have contributed to the main analyses of this review. Moreover, we identified 17 additional references that were also assessed as awaiting classification because we could not retrieve a full text to determine their eligibility. These references were mostly from the 1980s and 1990s, so it is likely that their outcomes would not be able to be incorporated into our main analyses. </p> <p>Although reporting of the timing of adverse events has improved in recent years, we were unable to identify the timing of their occurrence in the included reports, as required by the CONSORT‐Harms statement (<a href="./references#CD001423-bbs2-0138" title="JunqueiraDR , ZorzelaL , GolderS , LokeY , GagnierJJ , JuliousSA , et al. CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials. BMJ2023;381:e073725. [DOI: 10.1136/bmj-2022-073725]">Junqueira 2023</a>; <a href="./references#CD001423-bbs2-0154" title="PhillipsR , HazellL , SauzetO , CorneliusV . Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open2019;9(2):e024537. [DOI: 10.1136/bmjopen-2018-024537.]">Phillips 2019</a>). We therefore did not disaggregate data according to the length of follow‐up of the studies, since most of them described adverse events that were related to treatment initiation (gastrointestinal intolerance) or the effect of co‐interventions (e.g. dizziness and hypotension due to tamsulosin), which resulted in our assumption that they were all short term. </p> <p>We could not incorporate the results of five studies in our meta‐analyses due to missing data (missing standard deviation or standard error), but we reported these results separately (<a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a>; <a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a>; <a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a>; <a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a>; <a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a>). Finally, we could not perform many predefined funnel plots and subgroup and sensitivity analyses due to the scarcity of data, low heterogeneity across comparisons, and few trials included in each comparison. </p> </section> <section id="CD001423-sec-0087"> <h3 class="title" id="CD001423-sec-0087">Agreements and disagreements with other studies or reviews</h3> <p>A recent systematic review and network meta‐analysis on the same topic included 22 randomized clinical trials with multiple comparisons of hexanic and non‐hexanic extracts of <i>Serenoa repens</i> with alpha‐adrenergic agonists and placebo (<a href="./references#CD001423-bbs2-0159" title="RussoGI , ScanduraC , Di MauroM , CacciamaniG , AlbersenM , HatzichristodoulouG , et al. Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. Eur Urol Focus2021;7(2):420-431.">Russo 2021</a>). While the authors concluded that there were clinically insignificant improvements in IPSS at 12 weeks, their confidence intervals included little to no difference compared to placebo (MD −0.47, 95% CI −2.69 to 1.74 for hexanic extract; MD −1.69, 95% CI −4.36 to 0.98 for non‐hexanic extract). Moreover, the authors reported greater improvements in hexanic extracts than in non‐hexanic extracts. Still, the quantitative estimate included little to no difference between subgroups, similar to the findings of our review (MD −2.16, 95% CI −5.64 to 1.30). Finally, this review was limited due to fewer studies comparing <i>Serenoa repens</i> with placebo (7 in that review compared to 15 in ours), with a substantial imprecision in their results. </p> <p>Another systematic review included seven randomized clinical trials comparing hexanic extract (restricted to the Permixon formulation) with placebo for the outcomes of nocturia, Q<sub>max</sub>,and adverse events, but did not assess IPSS (<a href="./references#CD001423-bbs2-0150" title="NovaraG , GiannariniG , AlcarazA , Cózar-OlmoJM , DescazeaudA , MontorsiF , et al. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol Focus2016;2(5):553-561.">Novara 2016</a>). The authors found a decrease in the episodes of nocturia that may be clinically insignificant (MD −0.31, range −0.59 to −0.03); however, the findings on adverse events were similar to ours. </p> <p>Finally, a systematic review including 15 randomized clinical trials and 12 observational studies comparing Permixon with placebo assessed nocturia, Q<sub>max</sub>,and adverse events, but did not assess IPSS (<a href="./references#CD001423-bbs2-0166" title="Vela-NavarreteR , AlcarazA , Rodríguez-AntolínA , Miñana LópezB , Fernández-GómezJM , AnguloJC , et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon(®) ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int2018;122(6):1049-1065.">Vela‐Navarrete 2018</a>). This review also found a small reduction in nocturia that may be clinically insignificant (MD −0.64, range −0.98 to −0.31), and similar results regarding adverse events. </p> <p>Whereas the dose for almost all studies was 320 mg daily, higher concentrations may result in small but positive improvements in LUTS symptoms, as described in a single study that included doses of 400 mg (<a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a>). The data were insufficient to conduct a subgroup analysis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001423-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001423-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 1: Urologic symptom score (short term—sensitivity analysis)" data-id="CD001423-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 1: Urologic symptom score (short term—sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 2: Urologic symptom score (short term—all studies)" data-id="CD001423-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 2: Urologic symptom score (short term—all studies) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 3: Quality of life (short term—sensitivity analysis)" data-id="CD001423-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 3: Quality of life (short term—sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 4: Quality of life (short term—all studies)" data-id="CD001423-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 4: Quality of life (short term—all studies) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 5: Adverse events (sensitivity analysis)" data-id="CD001423-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 5: Adverse events (sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 6: Adverse events" data-id="CD001423-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 6: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 7: Urologic symptom score (subgroup analysis—hexanic vs non‐hexanic extract)" data-id="CD001423-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 7: Urologic symptom score (subgroup analysis—hexanic vs non‐hexanic extract) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 8: Urologic symptom score (long term—sensitivity analysis)" data-id="CD001423-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 8: Urologic symptom score (long term—sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 9: Urologic symptom score (long term—all studies)" data-id="CD001423-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 9: Urologic symptom score (long term—all studies) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 10: Quality of life (long term—sensitivity analysis)" data-id="CD001423-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 10: Quality of life (long term—sensitivity analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Serenoa repens versus placebo or no intervention, Outcome 11: Quality of life (long term—all studies)" data-id="CD001423-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: <i>Serenoa repens</i> versus placebo or no intervention, Outcome 11: Quality of life (long term—all studies) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Serenoa repens in combination with other phytotherapy versus placebo or no intervention, Outcome 1: Urologic symptom score" data-id="CD001423-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: <i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention, Outcome 1: Urologic symptom score </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001423-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/urn:x-wiley:14651858:media:CD001423:CD001423-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Serenoa repens in combination with other phytotherapy versus placebo or no intervention, Outcome 2: Adverse events" data-id="CD001423-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_t/tCD001423-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: <i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/media/CDSR/CD001423/image_n/nCD001423-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001423-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Serenoa repens compared to placebo or no intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>Serenoa repens</i> compared to placebo or no intervention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> lower urinary tract symptoms due to benign prostatic hyperplasia </p> <p><b>Setting</b>: outpatient (Australia, Asia, Europe, and the USA) </p> <p><b>Intervention</b>: <i>Serenoa repens</i> </p> <p><b>Comparison</b>: placebo/no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with <i>Serenoa repens</i> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom score</b><br/>Measured by IPSS scores (range 0 to 35)<br/>Higher scores indicate worse symptoms.<br/>Follow‐up: 3 to 6 months </p> <p>MCID: 3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1681</p> <p>(9 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −0.90</p> <p>(−1.74 to −0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean score was 14.33.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.90 lower</b> (1.74 lower to 0.07 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/>Measured by IPSS‐QoL score (range 0 to 6)<br/>Follow‐up: 3 to 6 months </p> <p>MCID: 0.5 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1001</p> <p>(5 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>High</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −0.20</p> <p>(−0.40 to 0.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean score was 3.11.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.20 lower</b> (0.40 lower to 0.00 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>Cumulative incidence<br/>Follow‐up: 1 to 17 months </p> <p>MCID: relative risk reduction/increase of 0.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2399</p> <p>(12 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> </p> <p>(0.77 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 more per 1000 (38 fewer to 51 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS</b> : International Prostate Symptom Score; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>QoL</b> : quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>We did not downgrade the certainty of the evidence for risk of bias as these results were robust following sensitivity analysis excluding studies at high risk of bias. <br/><sup>b</sup>We did not downgrade the certainty of the evidence for risk of bias as these results were robust following sensitivity analysis excluding studies at high risk of bias. We downgraded one level due to imprecision as the CI included little to no benefit and also harms (based on a 25% relative risk reduction). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Serenoa repens compared to placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001423-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Serenoa repens in combination with other phytotherapy versus placebo or no intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>Serenoa repens</i> in combination with other phytotherapy versus placebo or no intervention</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> lower urinary tract symptoms due to benign prostatic hyperplasia </p> <p><b>Setting</b>: outpatient (Europe/USA) </p> <p><b>Intervention</b>: <i>Serenoa repens</i> with other phytotherapy </p> <p><b>Comparison</b>: placebo/no intervention </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo/no treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk difference with <i>Serenoa repens</i> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urologic symptom score</b><br/>Measured by IPSS scores (range 0 to 35)<br/>Higher scores indicate worse symptoms.<br/>Follow‐up: 12 to 24 weeks </p> <p>MCID: 3 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>460</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD −2.41</p> <p>(−4.54 to −0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean score was 12.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.41 lower</b> (4.54 lower to 0.29 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b><br/>Measured by IPSS‐QoL score (range 0 to 6)<br/>Follow‐up: 2 to 6 months </p> <p>MCID: 0.5 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265</p> <p>(2 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c,d,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>1 study reported improvements (P &lt; 0.05), while the other did not.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b><br/>Cumulative incidence<br/>Follow‐up: 12 to 48 weeks </p> <p>MCID: relative risk reduction/increase of 0.25</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>481</p> <p>(4 RCTs)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.91</b> </p> <p>(0.58 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 fewer per 1000</p> <p>(55 fewer to 54 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPSS</b> : International Prostate Symptom Score; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>QoL</b> : quality of life; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to concerns about inconsistency: high statistical inconsistency (I<sup>2</sup> = 67%).<br/><sup>b</sup>Downgraded one level due to imprecision: wide CI including substantial benefit and little to no effect.<br/><sup>c</sup>Downgraded one level due to risk of bias: high risk of bias in included studies.<br/><sup>d</sup>Downgraded one level due to inconsistency: the included studies reported different effects.<br/><sup>e</sup>Downgraded one level due to imprecision: the included studies reported P values, and we are uncertain about effect sizes.<br/><sup>f</sup>Downgraded two levels due to imprecision: CI includes substantial benefits and harms. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Serenoa repens in combination with other phytotherapy versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001423-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Trial period</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Brand and daily dosage (when available)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Co‐intervention</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Age mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>IPSS mean (SD)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Prostate volume mean (SD)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>C</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>I</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>C</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Studies comparing <i>Serenoa repens</i> with placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0001" title="ArgirovicA , ArgirovicD . Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?Vojnosanit Pregl2013;70(12):1091-6. [PMID: 24450252]ArgirovicD . Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: The Comb TAMSR trial. European Urology Supplements2009;8(8):574-574. ">Argirović 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serbia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostamol Uno 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.9 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 (3.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2 (4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 (11.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0003" title="Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30 (Published 12 March 2010). ">BASTA 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2006 to 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>International</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg daily</p> <p>Prostamol Uno 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.61 (7.69)</p> <p>65.14 (7.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.14 (7.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0002" title="AndrioleGL , McCullum-HillC , SandhuGS , CrawfordED , BarryMJ , CantorA . The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. Journal of Urology2013;189(2):486‐492. AvinsAL , LeeJY , MeyersCM , BarryMJ . Safety and toxicity of saw palmetto in the CAMUS trial. Journal of Urology2013;189(4):1415-1420. BarryMJ , MelethS , LeeJY , KrederKJ , AvinsAL , NickelJC , et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA2011;306(12):1344-51. [clinicaltrials.gov ID: NCT00603304]CantorA , BarryM . Factors that affect men's feelings about their urination: findings from a multi-center clinical trial of phytotherapy to treat lower urinary tract symptoms. Clinical Trials (London, England)2012;9(4):498. CrawfordED , SullivanKF , AranguaP , LeeJ , LensingS , O'DonnellCI . Comparison of the american urological association symptom index with a short version, uwin, in a clinical phytotherapy trial. Journal of Urology2012;187(4 SUPPL. 1):e700. HelfandBT , LeeJY , SharpV , FosterH , NaslundM , WilliamsOD , et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. Journal of Urology2012;188(6):2288-2293. HelfandBT , McVaryKT , MelethS , SharpV , FosterH , NaslundM , et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. Journal of Urology2011;185(6):2223-2228. HelfandBT , SharpV , WilliamsOD , FosterH , NaslundM , LeeJ , et al. Improvements in lower urinary tract symptom severity are associated with improvements in sleep disturbance over time. Journal of Urology2012;187(4):e703-e704. LeeJ , AndrioleG , AvinsA , CrawfordED , FosterH , KaplanS , et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clinical Trials (London, England)2009;6(6):628‐636. LeeJ , BarryM , KusekJ . Participant perception of treatment assignment is related to symptom severity in a clinical trial of phytotherapy. Clinical Trials2012;9(4):521. LeeJY , FosterHE , McVaryKT , MelethS , StavrisK , DowneyJ , et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. Journal of Alternative and Complementary Medicine (New York, NY)2011;17(5):469‐472. LeeJY , MooreP , KusekJ , BarryM . Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto. Journal of Alternative and Complementary Medicine (New York, NY)2014;20(1):48‐52. NCT00603304. Complementary and alternative medicine for urological symptoms (CAMUS). https://clinicaltrials.gov/ct2/show/NCT00603304 (first received 29 January 2008). [NCT00603304]RoehrbornC , McVaryK , NickelJ , CrawfordE , KrederK , NaslundM , et al. The effect of increasing doses of a saw palmetto fruit extract on lower urinary tract symptoms attributed to benign prostatic hyperplasia: a randomized trial. Urology2011;78(3 SUPPL. 1):S14. ">Barry 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008 to 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prosta Urgenin Uno 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.25 (8.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.7 (8.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.42 (4.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.69 (4.75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0004" title="BauerHW , CasarosaC , CosciM , FrattaM , BlessmannG . Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study [Behandlung der benignen Prostatahyperplasie mit Sabalfrucht-Extrakt: Wirksamkeit und Verträglichkeit - Ergebnisse einer plazebokontrollierten Doppelblindstudie]. MMW Fortschritte der Medizin1999;141(25):127-32. ">Bauer 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany/Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Talso Uno 320 mg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>66.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0005" title="BentS , KaneC , ShinoharaK , NeuhausJ , HudesE , GoldbergH , et al. Saw palmetto for benign prostatic hyperplasia. The New England Journal of Medicine2006;354(6):557-66. [CLINICALTRIALS.GOV: NCT00037154] [DOI: 10.1056/NEJMoa053085]BentS , KaneCJ , ShinoharaK , GoldbergH , NeuhausJ , AvinsA . A randomized controlled trial of saw palmetto for the treatment of benign prostatic hyperplasia. Journal of Urology2005;173(4):443-443. NCT00037154. Saw Palmetto Extract in Benign Prostatic Hyperplasia. https://clinicaltrials.gov/ct2/show/NCT00037154 First Posted: May 17, 2002. ">Bent 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2001 to 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbon dioxide extract 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9 (8.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.0 (7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.7 (5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.0 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.7 (13.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.9 (15.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0006" title="BoccafoschiC , AnnosciaS . Serenoa repens extract and placebo in prostatic benign hyperplasia: clinical results [Confronto fra estratto di serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica]. Urologia1983;50:1257-68. [DOI: 10.1177/039156038305000615]">Boccafoschi 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (55 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (54 to 78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0008" title="ChampaultG , PatelJC , BonnardAM . A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. British Journal of Clinical Pharmacology1984;18:461-2. [DOI: 10.1111/j.1365-2125.1984.tb02491.x] [MEDLINE: 1985023088]">Champault 1984</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0010" title="DescotesJL , RambeaudJJ , DeschaseauxP , FaureG . Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after the exclusion of placebo responders. Clinical Drug Investigation1995;5:291-7. ">Descotes 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.6 (8.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0011" title="GerberGS , KuznetsovD , JohnsonBC , BursteinJD . Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology2001;58(6):960-4. [DOI: 10.1016/s0090-4295(01)01442-x]">Gerber 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 to 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SR 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 (± 9.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.3 (± 9.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.7 (± 4.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8 (± 4.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0012" title="GlémainP , CoulangeC , BillebaudT , GattegnoB , MuszynskiR , LoebG , et al. Tamsulosin with or without Serenoa repens in benign prostatic hyperplasia: the OCOS trial [Tamsulosine avec ou sans Serenoa repens dans l'hypertrophie bénigne de la prostate: l'essai OCOS]. Progrès en Urologie2002;12:395-403. ">Glémain 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.2 (7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.4 (7.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2 (5.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3 (5.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.8 (16.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 (15)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0013" title="HizliF , UygurMC . A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology2007;39:879-86. ">Hizli 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.2 (6.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.9 (5.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.6 (3.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.2 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2 (4.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.6 (11.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0014" title="HongH , KimCS , LeeJS , MaengWJ . Effects of Saw Palmetto Extracted Oil Supplementation on Human Benign Prostatic Hyperplasia. FASEB Journal2008;22:1108.6-1108.6. HongH , KimCS , MaengS . Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice2009;3(4):323-7. [DOI: 10.4162/nrp.2009.3.4.323] [PMID: 20098586]">Hong 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SR 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0017" title="MandressiS , TaralloU , MaggioniA , TomboliniP , RoccoF , Quadraccia. Medical treatment of benign prostatic hyperplasia: efficacy of the extract of Serenoa repens (Permixon®) compared to that of the extract of Pygeum africanum and a placebo [Terapia medica dell'adenoma prostatico: confronto della efficacia dell'estratto di serenoa repens (Permixon®) versus l'estratto di pigeum africanum e placebo]. Urologia1983;50(4):752-8. ">Mandressi 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0022" title="Reece SmithH , MemonA , SmartCJ , DewburyK . The value of Permixon in benign prostatic hypertrophy. British Journal of Urology1986;58:36-40. ">Reece Smith 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.15 (5.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.03 (6.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0023" title="RyuYW , LimSW , KimJH , AhnSH , ChoiJD . Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia Internationalis 94;2:187-93. [DOI: 10.1159/000366521] [PMID: 25614155]">Ryu 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2012 to 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permixon* 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.5 (1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.4 (1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6 (0.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.1 (0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.2 (0.67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0024" title="ShiR , XieQ , GangX , LunJ , LifeC , PantuckA , et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. The Journal of Urology2008;179:610-5. ">Shi 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostataplex (dosing not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0025" title="SudeepHV , ThomasJV , ShyamprasadK . A double blind, placebo-controlled randomized comparative study on the efficacy of phytosterol-enriched and conventional saw palmetto oil in mitigating benign prostate hyperplasia and androgen deficiency. BMC Urology2020;20(1):86. [DOI: 10.1186/s12894-020-00648-9] [PMID: 32620155]">Sudeep 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>India</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VISPO/SPO 400 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.76 (7.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.18 (8.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.00 (4.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.00 (3.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0026" title="WillettsKE , ClementsMS , ChampionS , EhsmanS , EdenJA . Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. British Journal of Urology International2003;92:267-70. ">Willetts 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999 to 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbon dioxide extract 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1 (1.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.9 (1.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0027" title="ChiCTR-TRC-13003575. Effects of Saw Palmtto extract in binign prostatic hyperplasia and sexual function: a multicenter, randomized, double-blind, placebo-controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=5985 10 September 2013. YeZ , HuangJ , ZhouL , ChenS , WangZ , MaL , et al. Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. Urology2019;129:172-179. [DOI: 10.1016/j.urology.2019.02.030] [PMID: 30880074]">Ye 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014 to 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SR 320 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.47 (5.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.32 (5.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.42 (3.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.34 (4.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.0 (19.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.3 (25.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="13" rowspan="1" valign=""> <p><b>Studies comparing phytotherapy containing <i>Serenoa repens</i> with placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0007" title="CarbinBE , LarssonB , LindahlO . Treatment of benign prostatic hyperplasia with phytosterols. British Journal of Urology1990;66(6):639-41. [MEDLINE: 1991091633]">Carbin 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sweden/Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Curbicin</p> <p>(PSO 480 mg + SR 480 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 (6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.2 (5.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0009" title="ACTRN12610000168055. A study looking at the effectiveness of a oral herbal supplement for helping to manage the symptoms of enlarged prostate. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12610000168055 19/02/2010. CoulsonS , RaoA , BeckSL , SteelsE , GramotnevH , VitettaL . A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complementary Therapies in Medicine2013;321(3):172-9. [ANZCTR: 12610000168055] [DOI: 10.1016/j.ctim.2013.01.007] [PMID: 23642948]">Coulson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ProstateEZE Max</p> <p>(PSO 160 mg, epilobium 500 mg, lycopene 2.1 mg, pygeum 15 g + SR 660 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63 (10.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.9 (9.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0015" title="IaconoF , RuffoA , PreziosoD , RomeoG , IllianoE , RomisL , et al. Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients: PS-04-009. Journal of Sexual Medicine2015;2(Suppl 3):201. [DOI: 10.1111/jsm.12872_2]">Iacono 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tradamixina</p> <p>(<i>Eisenia</i> 80 mg, <i>Tribulus</i> 100 mg, chitosan oligosaccharide (Biovis) 100 mg + SR 320 mg) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>64.2 (8.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6 (5.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0016" title="LopatkinN , SivkovA , SchläfkeS , FunkP , MedvedevA , EngelmannU . Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms—long-term follow-up of a placebo-controlled, double-blind, multicenter trial. International Urology and Nephrology2007;39(4):1137‐1146. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Combined extract of sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in the double blind, placebo-controlled trial. World Journal of Urology2005;23(2):139-46. LopatkinN , SivkovA , WaltherC , SchläfkeS , MedvedevA , AvdeichukJ , et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. World Journal of Urology2005;23(2):139‐146. LopatkinNA , SivkovAV , MedvedevAA , WalterK , SchlefkeS , Avdeĭchuk IuI, et al. Combined extract of Sabal palm and nettle in the treatment of patients with lower urinary tract symptoms in double blind, placebo-controlled trial. Urologiia (Moscow, Russia : 1999)2006;(2):12, 14‐9. SivkovA , KöhlerS , EngelmannU , MedvedevA , LopatkinN . Long-term efficacy and safety of a combination of sabal and urtica extracts in LUTS—a placebo-controlled, double-blind, multicenter trial. Urologe A2001;40 (Suppl 1):S19. ">Lopatkin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 to 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Russia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO 160/120</p> <p>(Sabal‐Urtica 240 mg + SR 320 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.4 (3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.8 (3.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.5 (17.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.8 (17.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0018" title="MarksLS , PartinAW , EpsteinJI , TylerVE , SimonI , MacairanML , et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. The Journal of Urology2000;163(5):1451-6. SokollLJ , MarksLS , MikolajczykSD , BruzekDJ , MangoldLA , RittenhouseHG , et al. Effects of finasteride and saw palmetto on BPSA, propsa, and CPSA in men with benign prostatic hyperplasia. Journal of Urology2004;171(4):438-439. ">Marks 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1997 to 1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nettle root 240 mg, PSO 480 mg, lemon 99 mg, vitamin A 570 IU + SR 318 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.1 (8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.9 (9.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1 (7.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6 (5.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.5 (29.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.6 (26.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0019" title="MetzkerH , KieserM , HolscherU . Efficacy of a Sabal-Urtica Combination Drug in the Treatment of Benign Prostatic Hyperplasia (BPH) [Wirksamkeit eines Sabal-Urtica-kombinationspraparates bei der behandlung der benignen prostatahyperplasie (BPH)]. Der Urologe B1996;36(4):292-300. ">Metzker 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostagutt forte</p> <p>(Sabal‐Urtica 240 mg + SR 320 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0020" title="ISRCTN78639965. Serenoa repens, lycopene and selenium vs. tamsulosin for the treatment of lower urinary tract symptoms (LUTS)/ Benign prostatic hyperplasia (BPH). https://www.isrctn.com/ISRCTN78639965 Registration date: 11/12/2013. MorgiaG , RussoGI , VoceS , PalmieriF , GentileM , GiannantoniA , et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate2014;74(15):1471-80. [DOI: 10.1002/pros.22866] [PMID: 25154739]">Morgia 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2011 to 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Profluss</p> <p>(selenium and lycopene + SR 320 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tamsulosin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001423-bbs2-0021" title="PreussHG , MarcusenC , ReganJ , KlimbergIW , WelebirTA , JonesWA . Randomized trial of a combination of natural products (Cernitin, saw palmetto, beta-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International Urology and Nephrology2001;33:217-25. ">Preuss 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cernitin AF</p> <p>(Cernitin 378 mg, vitamin E 100 IU + SR with beta‐sitosterol 286 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p>(*) Hexanic extract of <i>Serenoa repens</i>; <b>C</b> : control; <b>I</b> : intervention; <b>IPSS</b> : International Prostate Symptom Score; <b>IU</b> : international units; <b>N/A</b> : not available (not described); <b>PSO</b> : pumpkin seed oil; <b>SR</b>: <i>Serenoa repens;</i><b>SD</b>: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/full#CD001423-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001423-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Serenoa repens versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Urologic symptom score (short term—sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.74, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Urologic symptom score (short term—all studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.44, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Quality of life (short term—sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.40, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Quality of life (short term—all studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.32, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events (sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.77, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2539</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Urologic symptom score (subgroup analysis—hexanic vs non‐hexanic extract) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.44, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Hexanic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.99, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Non‐Hexanic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.99 [‐1.91, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Urologic symptom score (long term—sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.75, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Urologic symptom score (long term—all studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.58, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Quality of life (long term—sensitivity analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.41, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Quality of life (long term—all studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.37, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Serenoa repens versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001423-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Serenoa repens in combination with other phytotherapy versus placebo or no intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Urologic symptom score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.41 [‐4.54, ‐0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.58, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Serenoa repens in combination with other phytotherapy versus placebo or no intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001423.pub4/references#CD001423-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001423.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001423-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001423-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001423-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001423-note-0016">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001423-note-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001423-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD001423-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD001423-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001423-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001423-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001423-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001423\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001423\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001423\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001423\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001423\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001423.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001423.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001423.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001423.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001423.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715267747"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001423.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715267751"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001423.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d82ea7834f446',t:'MTc0MDcxNTI2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 